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Abstract  
 
Parkinson’s disease (PD) is a massive chronic progressive disorder characterized 
by the intracellular depositions known as Lewy Bodies (LBs), mainly composed of alpha-
synuclein protein (aSyn). These proteinaceous aggregates are associated with the loss of 
dopaminergic neurons. aSyn aggregation is thought to be a key event in the PD 
pathogenesis leading to the formation of LBs.  
Thus is extremely important to search and explore therapeutic agents that prevent 
or reduce aSyn toxicity. The consumption of Polyphenols-rich foods and beverages has 
been suggested to limit the neurodegeneration associated with a variety of neurological 
disorders and to prevent or reverse abnormal deteriorations in cognitive performance. 
These metabolites are consider to exert modulatory actions on cellular systems through 
direct action on various signalling pathways. 
In this study it was analysed the effects mediated by a polyphenol-enriched 
fraction (PEF) from leaves of Corema album in a yeast model of PD expressing aSyn 
protein. In an effort to obtain new insights into the protective mechanisms of C. album 
leaf PEFs, as well as the signaling pathways potentially affected by their bioactivity and 
by aSyn expression, we performed a two-dimensional electrophoresis based quantitative 
and phosphoproteomic analysis. 
It was possible to find several proteins that were either differentially expressed or 
differentially phosphorylated in response to aSyn expression or due to the incubation of 
yeast cells with C. album leaf PEFs.  Also, the results obtained from growth and 
immunodetection assays suggest that C. album PEFs are able to protect yeast cells from 
the aSyn induced toxicity increasing their viability. 
These results imply C. album polyphenols from leaves, as potential therapeutic 
agent directed towards preventing the aSyn induced toxicity. The understanding of the 
molecular effects of polyphenols will open novel opportunities for the exploration of their 
molecular effects and for drug development. 
 
Keywords: Parkinson’s disease, aSyn, polyphenols, yeast, proteomics. 
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Resumo 
 
A doença de Parkinson (DP) é uma desordem neurodegenerativa, progressiva e 
crónica caracterizada por deposições intracelulares denominadas corpos de Lewy (CL), 
que são maioritariamente compostos pela proteína alfa-sinucleína (aSyn). Estes 
agregados proteináceos estão associados com a degeneração dos neurónios 
dopaminérgicos.  
Assim é extremamente importante investigar possíveis agentes terapêuticos que 
sejam capazes de reduzir ou prevenir a toxicidade da aSyn. O consumo de alimentos e 
bebidas ricos em polifenóis estão associados a uma limitação na neurodegeneração 
associada a várias desordens neurológicas e a prevenir ou reverter deteriorações na 
performance cognitiva. Estes metabolitos exercem alterações nos sistemas celulares 
através do interação com várias vias de sinalização.  
Neste estudo foi analisado o efeito de frações enriquecidas em polifenoís (FEPs) 
de folhas de C. album num modelo de PD em levedura com expressão da proteína aSyn. 
Num esforço para obter novo conhecimento em relação ao mecanismo de proteção dos 
PEFs da folha de C. album, assim como, potencias vias de sinalização afetadas pela sua 
bioatividade e pela expressão da aSyn, foi realizada uma análise quantitativa e 
fosfoproteomica através da eletroforese bidimensional. 
Foi possível encontrar várias proteínas que são diferencialmente expressas ou 
fosforiladas em resposta à expressão da aSyn ou devido à incubação das leveduras com 
PEFs da folha de C. album. Além disso, os resultados obtidos a partir dos crescimentos 
celulares e ensaios de imunodetecção sugerem que os PEFs da folha de C. album são 
capazes de proteger as leveduras a partir da toxicidade induzida pela aSyn e aumentar a 
viabilidade celular.  
Estes resultados implicam os polifenóis de folhas de C. album, como potencial 
agente terapêutico para prevenir a toxicidade induzida pela aSyn. A compreensão dos 
efeitos moleculares dos polifenóis abrirá novas oportunidades para a exploração dos seus 
efeitos moleculares e desenvolvimento de agentes terapêuticos. 
 
Palavras-chave: Doença de Parkinson, aSyn, polifenóis, levedura, proteomica. 
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Resumo alargado 
 
As doenças neurodegenerativas são caracterizadas por morte neuronal excessiva 
e prematura em regiões focais do cérebro. Entre elas a doença de Parkinson (DP) é uma 
das mais comuns. 
 Em termos patológicos a DP é caracterizada por uma perda profunda e 
progressiva dos neurónios dopaminérgicos, localizados na SNpc do mesencéfalo, região 
localizada na porção superior do tronco encefálico, originando reduções de dopamina na 
via nigroestriatal. Esta perda progressiva dos neurónios dopaminérgicos está deve-se à 
presença de corpos de Lewy (CL), agregados proteicos compostos maioritariamente pela 
proteína aSyn. aSyn é uma proteína que está presente nos terminais pré-sinápticos onde 
se encontra associada ao trafego intracelular.  
A agregação desta proteína em CL esta associada a vários processos patológicos 
como disfunção mitocondrial e consequente stress oxidativo, disfunção do sistema da 
ubiquitina/proteassoma (UPS) e vias de autofagia, e bloqueio da libertação de dopamina 
nos terminais pré-sinápticos.  
Uma vez que a medicação atual apenas atenua sintomas da DP, sem parar ou 
retardar a degeneração de neurónios dopaminérgicos, existe uma necessidade urgente 
para a identificação de novos agentes terapêuticos que sejam capazes de contrariar a 
toxicidade da aSyn. Os polifenóis ou compostos fenólicos são fitoquímicos amplamente 
distribuídos no reino vegetal. Os polifenóis estão presentes em plantas, frutas e vegetais, 
incluindo pequenos frutos, azeite e vinho. O consumo de alimentos ricos em polifenóis 
tem sido associado a efeitos benéficos para a saúde humana. Estudos indicam que existe 
uma relação entre o consumo de alimentos ricos em polifenóis e uma diminuição da 
incidência de doenças neurodegenerativas.  
Estes compostos estão envolvidos num largo espectro de mecanismos de ação 
celulares, como é o caso da regulação de vias de sinalização relacionadas com a 
modulação de genes envolvidos em mecanismos morte sobrevivência e proliferação 
celular, regulação da função mitocondrial e ativação de moléculas antioxidantes 
endógenos. Assim, os compostos fenólicos surgem como candidatos a possíveis agentes 
terapêuticos na DP.  
A levedura Saccharomyces cerevisiae é um dos modelos biológicos mais versáteis 
para estudar doenças neurodegenerativas, devido ao facto de mecanismos relacionados 
com a disfunção mitocondrial e proteossomal e regulação transcricional serem 
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extremamente bem conservados entre leveduras e humanos, possibilitando assim estudar 
os mecanismos envolvidos neste tipo de doenças. 
Neste estudo o principal objetivo consiste em analisar o efeito de frações 
enriquecidas de polifenoís (FEPs) de folhas de Corema album, uma espécie Portuguesa, 
no proteoma e fosfoproteoma de um modelo biológico de PD em levedura. Com esta 
análise, torna-se possível estudar a rede de proteínas do nosso modelo de PD em levedura, 
bem como a modulação na expressão proteica mediada pelos polifenoís de C. album. 
 O primeiro passo deste trabalho consistiu na otimização de um modelo de PD em 
levedura. O modelo e composto por 3 estirpes de S. cerevisiae; aSyn-1 e aSyn-2 ambas 
com o mesmo genoma (MAT alpha can1-100 his3-11 15 leu2-3 112 ade2-1 GAL1pr-syn 
WT::TRP1 GAL1pr-syn WT::URA3) que possuem um plasmídeo integrativo, com 2 
cópias do gene SNCA (aSyn). A expressão da proteína aSyn é regulada por um promotor 
da galactose. Por ultimo, a estirpe controlo não apresenta o gene SNCA (can1-100 his3-
11 15 leu2-3 112 pRS304::TRP1 pRS306::URA3 ade2-1).  
Numa primeira análise foram realizadas curvas de crescimento para as estirpes 
aSyn-1, aSyn-2 e controlo em diferentes meios de cultura. Os resultados obtidos indicam 
que a expressão da proteína aSyn nas estirpes aSyn-1 e aSyn-2 é toxica levando a 
decréscimo na viabilidade celular das leveduras. Contudo, os resultados mostram que a 
estirpe aSyn-2 é mais sensível aos efeitos tóxicos de expressão aSyn, portanto, esta estirpe 
foi selecionada para os estudos posteriores. 
 A próxima etapa permitiu avaliar o efeito exercido por FEPs obtidas a 
partir de folhas de C. album em leveduras que expressam a proteína aSyn. Assim, usando 
duas metodologias, curvas de crescimento e “spot assays”, as estirpes controlo e aSyn-2 
foram incubadas com várias concentrações de FEPs de folhas de C. album. Em ambos os 
métodos foi possível observar que várias concentrações de FEPs de folhas de C. album 
reduzem a toxicidade induzida pela expressão da aSyn na estirpe aSyn-2, e promovem 
uma melhoria na viabilidade celular.  
Numa fase mais avançada do trabalho, a análise do proteoma total e 
fosfosproteoma por eletroforese bidimensional revelou que a expressão da aSyn e o 
tratamento das leveduras com FEPs de folhas de C. album promovem alterações na 
expressão proteica de várias proteínas. A análise do proteoma total permitiu encontrar 22 
proteínas que apresentaram variações seu padrão de expressão. Curiosamente foi 
verificado que a maioria dessas proteínas se encontra “downregulated” devido a 
expressão da aSyn, mas fascinantemente, o tratamento com PEFs recupera o padrão 
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normal de expressão dessas proteínas. Estes resultados sugerem que os PEFs de folhas de 
C. album possivelmente estão a modular vias sinalização inerentes à aSyn.  
Relativamente à análise do fosfoproteoma das estirpes controlo e aSyn-2, foram 
detetadas 10 proteínas que apresentaram variações no nível de fosforilação. Curiosamente 
foi observada uma tendência no nível de fosforilação apresentado por estas proteínas, 
onde a incubação das leveduras da estirpe aSyn-2 com FEPs reduz o nível de fosforilação 
comparativamente às leveduras da mesma estirpe que não receberam o tratamento. Foi 
observado que a expressão da aSyn aumenta a fosforilação na estirpe aSyn-2, 
relativamente estirpe controlo. A modulação dos níveis de fosforilação das proteínas 
devido ao tratamento com FEPs de folhas de C. album indica que estes compostos 
provavelmente possuem a capacidade de ativar ou inibir vias de sinalização relacionadas 
com a fosforilação proteica. Sabendo que a fosforilação da aSyn está implícita na 
formação dos CL, estes resultados sugerem que os polifenóis provenientes das folhas de 
C. album podem ser promissores agentes terapêuticos na DP.  
Observou-se ainda através de ensaios de imunodeteção que leveduras da estirpe 
aSyn-2 que foram incubadas com FEPs de C. album exibem níveis inferiores da proteína 
aSyn relativamente a leveduras que não tiveram o mesmo tratamento com FEPs. Tendo 
em conta vários estudos indicando que os polifenóis são agentes capazes de modular os 
sistemas de autofagia celular, estes resultados sugerem que a proteção mediada pelos 
FEPs da folha da C. album pode estar relacionada com a degradação da aSyn via 
autofagia.  
Apesar dos resultados promissores obtidos neste trabalho, estudos envolvendo a 
seleção de subproteomas serão necessários para uma melhor compressão dos mecanismos 
subjacentes aos efeitos neuroprotetores mediados pelos polifenóis das folhas de C. album. 
 
 
Palavras-chave: Doença de Parkinson, levedura, polifenóis, aSyn, Frações 
enriquecidas de polifenóis 
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Goals  
 
Neurodegenerative diseases are multifactorial and currently there is no effective 
therapy against the progressive neuronal death characteristic of these pathologies. It is 
therefore very important to find new therapeutic strategies that can prevent and / or delay 
the neurodegeneration process. Plant polyphenols appear in response to this demand, 
having been reported to have substantial neuroprotective activity. 
S. cerevisiae is one of the most versatile biological systems used as a model for 
the study of neurodegenerative diseases. C. album leaf PEFs protective effect was already 
defined in a yeast PD model.   
The main objective of this study is to access the effect of C. album leaf PEFs on 
proteome and phosphoproteome of the yeast model of PD. This analysis will be done 
using two dimensional gels of proteins and will require optimization of the technique 
involved. A detailed analyses of the protein profiles obtained using appropriate software 
for image analysis will allow to find proteins that respond to effect of aSyn expression 
and to the treatment with C. album leafs PEFs. The Identification of those proteins will 
contribute to the overall understanding of our PD yeast model and neuroprotective effects 
of C. album leaf PEFs.  
 
 
 
Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: 
phosphoproteome alterations was a work developed between the Disease and Stress 
Biology Laboratory (DSB), from Instituto de Tecnologia Química e Biológica (ITQB) – 
Universidade Nova de Lisboa and Cellular and Molecular Neuroscience Unit, from 
Instituto de Medicina Molecular, from Faculdade de Medicina – Universidade de Lisboa. 
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Introduction 
 
 Neurodegenerative Diseases 
 
Human neurodegenerative diseases are characterized by the progressive loss of 
structure and/or function of neurons, leading to their death. 
Neurodegenerative disorders such as Parkinson’s (PD) and Alzheimer‘s (AD) 
diseases account for a significant and increasing proportion of morbidity and mortality in 
the recent world. The most common risk factor for developing neurodegenerative 
diseases, is aging. With the rise in human lifespan around the world in the last years, the 
incidence of neurodegenerative diseases, especially AD or PD, has increased 
dramatically. United Nations population projections estimate a world population of 400 
million people over 80 years by the year 2050. Therefore, it is expected that over the next 
generation, the percentage of elderly people will double and consequently the proportion 
of persons suffering from some kind of neurodegenerative diseases. 
As the population ages, an improved understanding of these diseases will be vital to 
developing more effective therapies and combating the staggering personal, social, and 
economic costs of these diseases1–3.  
 
 Parkinson’s disease, definition and historical perspective 
  
PD was first described in 1817 by James Parkinson in his monograph ''An essay on 
the shaking palsy'', where he identifies six cases of PD4–7. Previously referred to as 
‘‘paralysis agitans’’, nowadays PD is among the most prevalent neurodegenerative 
disorders as it affects approximately 6 million individuals worldwide8,9. Generally, the 
onset of PD occurs in patients over the age of 50 years and its incidence slowly progresses 
with increasing age, affecting about 2% of people over 65 years old9–11. Clinical 
manifestations of PD consists in a series of severe motor defects produced by resting 
muscle tremor, muscle rigidity, brandykinesia and postural instability6,8–10. Brandykinesia 
refers to slowness of movement, and may significantly impair the quality of life. 
Brandykinesia is considered to be the main feature and the necessary condition for 
diagnosis of PD6–8. These motor disabilities begin to be felt by patients with about 5-10 
years of disease, even when treated with symptomatic medication available7.  
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Table 1- Parkinson’s disease symptoms (Adapted from reference6 ) 
 
All these motor symptoms are thought to arise primarily from the loss of dopaminergic 
(DA) neurons within the “substancia nigra pars compacta” (SNpc), located 
in mesencephalon8.  
Almost two centuries after the first description of PD, there are only symptomatic 
treatments available for this pathology, which essentially involves substituting dopamine, 
or suppressing pathological neuronal oscillations via deep brain stimulation10,12.  
 The discovery of levodopa in 1960 revolutionized the treatment of PD. Levodopa has 
the ability to restore dopaminergic transmission deficiency and provides remarkable 
symptomatic relief to the vast majority of these patients. This remains the most 
efficacious agent available for PD treatment. However, we soon learned that after several 
years of treatment most patients develop involuntary movements termed “dyskinesias,” 
which are difficult to control and significantly impair the quality of life7,9,13.  
As a result, in the recent years efforts have been made to develop new therapeutic 
approaches to treat PD. Interventions such as stem-cell transplantation and gene therapies 
have been examined as potential treatments for PD. Although early results indicated that 
patients may obtain long-term clinical benefit from the intrastriatal transplantation of 
human embryonic mesencephalic tissue, it later became clear that there are several 
restrictions to stem cell therapy. These include the limited availability of fetal human 
mesencephalic tissue and the usually very low percentage of viable transplanted cells9. 
On the other hand, in the case of gene therapy, viral vectors have proven to be an ideal 
Motor Symptoms Non-Motor Symptoms 
 Tremor, Brandykinesia, rigidity, postural 
instability 
 Hypomimia, dysarthria, dysphagia, sialorrhoea 
 Decreased arm swing, shuffling gait, 
festination difficulty arising from chair, turning 
in bed 
 Micrographia, cutting food, feeding, hygiene, 
slow activities of daily living 
 Glabellar reflex, blespharospasm, dystonia, 
strial deformity, scoliosis, camptocormia 
 
 Cognitive impairment, brandyphrenia, tip-of-
the-tongue phenomenon 
 Depression, apathy, anhedonia, fatigue 
 Sensory symptoms: anosmia, ageusia, 
paresthesias  
 Dysautonomia (orthostatic hypotension, 
constipation, urinary and sexual dysfunction, 
abnormal sweating, seborrhoea), weight loss 
 Sleep disorders (behavior disorder, vivid 
dreams, daytime drowsiness, sleep 
fragmentation, restless legs syndrome) 
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vehicle to deliver or silence genes of interest in the brain in order to develop genetic 
strategies. Still none of these approaches could stop the degeneration of dopaminergic 
neurons9.  
Our capacity to discover new PD treatment is limited for several reasons; one of them 
relates to the complex and multifactorial etiology of PD, which involves an intricate 
interplay of a large network of factors: genes, environment and gene-environment 
interactions, lack of knowledge of the specific molecular events that provoke 
neurodegeneration and aging5,7,12.  
 
 Genetic determinants of Parkinson’s disease 
 
In the last decades the discovery of several genes linked to rare familial forms of PD 
came to prove the role of genetics in disease development and brought new evidence for 
understanding the pathological mechanisms of PD. The majority of cases are thought to 
be idiopathic. Nevertheless, in 5-10% of cases, PD presents as a Mendelian form 
displaying both recessive and dominant models of inheritance8,14–16. Several genetic loci 
named PARK are identified to cause PD (Table 2) These include two autosomal dominant 
genes, SNCA encoding alpha-synuclein (aSyn), and leucine-rich repeat kinase 2  
(LRRK2), and four autosomal recessive genes, encoding Parkin, DJ-1, PTEN-induced 
kinase1 (PINK1) and ATPase type 13A2 (ATP13A2)8,14,15. 
SNCA gene point mutations (A53T, A30P, E46K, H50Q and G51D), also assigned as 
PARK1, as well as duplications and triplications, cause autosomal dominant PD16–18. On 
the other hand Parkin function as an E3 ubiquitin ligase by targeting misfolded proteins  
to the ubiquitin proteasome pathway for degradation. The loss of its E3 ligase activity 
lead to autosomal recessive early onset PD15. PINK1 mutations are the second most-
common cause of autosomal recessive PD after Parkin. PINK1 is located in the 
mitochondria and mutations in the kinase domain of the protein lead to a mitochondrial 
dysfunction and dopaminergic neuronal degeneration, as they result in impaired 
phosphorylation of its substrates in mitochondria15,16,19. Loss of function mutations in the 
DJ-1 gene are associated with forms of autosomal recessive early-onset Parkinsonism. 
DJ-1 is thought to protect neurons from oxidative stress by acting as redox-dependent 
chaperone, preventing misfolding and aggregation of oxidized mitochondrial proteins. 
Accordingly with this DJ-1 knockout mice presents motor impairments and dopaminergic 
dysfunction15,16,20. Mutations in the LRRK2 gene cause autosomal dominant PD. This 
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protein contains several domains, including RAS/GTPase, tyrosine kinase, MAPKK and 
leucine-rich-repeat domain, in which mutations can affect signaling pathways relevant in 
PD5. Finally, mutations in ATP13A2 cause an atypical form of PD with dementia, named 
Kufor-Rake syndrome8.  
 
Table 2- Genetic factors with PARK status in PD. ADo, autosomal dominant; AR, autosomal recessive. 
(Adapted from reference8,14,15) 
 
 
 Hallmarks of Parkinson’s disease 
 
Pathological hallmarks of PD are loss of dopaminergic neurons in “substancia nigra 
pars compacta”, and the presence of intraneuronal proteinacious cytoplasmic inclusions 
named Lewy Bodies (LBs)5,8,10,11,21–24. 
LBs are cellular inclusions that can be visualized by histological analysis and are 
predominantly constituted by the presynaptic protein aSyn, a small acid protein involved 
in both sporadic and familial cases of PD5,7,8,10,12,21–23. LBs present a spherical structure 
with more than 15 μm in diameter and have a organized structure containing a dense 
hyaline core surrounded by a clear halo7 (Fig.1). 
 
 
Locus 
 
Gene 
 
Inheritance 
 
Probable function 
 
Chromosome 
PARK1 
 
PARK2 
 
PARK6 
 
PARK7 
 
PARK8 
 
PARK9 
SNCA (alpha-synuclein) 
 
Parkin 
 
PINK-1 
 
Dj-1 
 
LRRK2 
 
ATP13A2 
ADo 
 
AR 
 
AR 
 
AR 
 
ADo 
 
AR 
Presynaptic protein, Lewy Body 
 
E3 ubiquitin ligase 
 
Mitochondrial Ser-Thr kinase 
 
Redox-dependent molecular 
chaperone 
Leucine-rich repeat containinig 
kinase 
Neuronal P-type ATPase 
4q21 
 
6q25.2-27 
 
1p35-36 
 
1p36 
 
12q12 
 
1p36 
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Figure 1: Immunohistochemical labeling of intraneuronal inclusions, termed LBs, in the SNpc 
dopaminergic neuron. Immunostaining with an antibody against aSyn reveals a LB (black arrow) with an 
intensely immunoreactive central zone surrounded by a faintly immunoreactive peripheral zone (left 
image). Conversely, immunostaining with an antibody against ubiquitin yields more diffuse 
immunoreactivity within the LB (right image). (Adapted from reference7) 
 
PD is often unremarkable, with mild frontal atrophy in some cases, but there is no 
significant atrophy of brainstem. However, in the SNpc, it can be found the cell bodies of 
nigrostriatal neurons and these are projected primarily to the putamen (Fig.2). The loss of 
these neurons, which normally contain amounts of neuro-melanin, produces the classic 
neuropathological finding of SNpc depigmentation7,25.  Sections of the brainstem usually 
reveal loss of the normally dark black pigment in the SNpc (Fig. 2).This loss of 
pigmentation correlates with neuronal loss of dopaminergic neurons in the SNpc and 
noradrenergic neurons in the locus ceruleus7,25. 
 Indeed, the spreading of LBs correlates with the progression of the disease. In PD, 
generally LBs are mainly found at sites of neuronal loss such as the SNpc thus indicating 
that their presence may be related to nerve cell loss9,26.  
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The aSyn deposition which is the main constituent of the LBs is thought to be central 
to the pathogenesis of PD. Recent findings have suggested that aSyn deposition at the 
synapse may be the key issue of the neurodegenerative process. The crucial role of aSyn 
in PD pathophysiology is further sustained by findings showing that the areas that 
degenerate in PD (SNpc, striatum and ventral tegmental area) express low levels of aSyn 
in physiological conditions suggesting that these regions may be more vulnerable to a 
pathological increase of its levels, which normally occurs during aging4,9. 
 
 
 
 
Loss of 
Dopaminergic 
Neurons 
a) Normal Brain b) Parkinson’s Disease Brain 
Figure 2: Neuropathology of PD a) Schematic representation of the normal nigrostriatal pathway (in red). It is 
composed of dopaminergic neurons whose cell bodies are located in the substantia nigra pars compacta (SNpc; 
see black arrows). These neurons project (thick solid red lines) to the basal ganglia and synapse in the striatum 
(i.e., putamen and caudate nucleus). The image demonstrates the normal pigmentation of the SNpc, produced by 
neuromelanin within the dopaminergic neurons. b) Schematic representation of the diseased nigrostriatal pathway 
(in red). In PD, the nigrostriatal pathway degenerates. There is a marked loss of dopaminergic neurons that project 
to the putamen (dashed line) and a much more modest loss of those that project to the caudate (thin red solid line). 
The image demonstrates depigmentation (i.e., loss of dark-brown pigment neuromelanin; see black arrows) of the 
SNpc due to the marked loss of dopaminergic neurons. (Adapted from reference7). 
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 Alpha-Synuclein: structural and functional properties 
 
aSyn is an abundant, 140 amino acid long, neuronal cytoplasmic protein. The 
sequence of aSyn gene (SNCA) has a high degree of conservation in numerous organisms, 
and mutations or multiplications of this gene have been associated with familial forms of 
PD4,9. 
 aSyn is predominantly localized to presynaptic terminals in the central nervous 
system (CNS), where it is freely associated with synaptic vesicles5. It belongs to the 
synuclein family, which includes also β- and γ-synuclein. These proteins have a common 
N-terminal sequence containing a different number of repeated regions while they differ 
in the C-terminal region4,9.  
While all the synucleins are present in human brain, only aSyn is show to be associated 
with pathological structures in neurodegenerative conditions27. Sequence analysis 
suggests that aSyn consists of three distinct regions: the N-terminal amphipathic region 
(residues 1-60), the central hydrophobic Non-amyloid-β-component (NAC) region 
(residues 61-95), and the C-terminal acidic region (residues 96-140)4,9,22,27. 
The N-terminal half of aSyn contains four 11-amino acid imperfect repeats with a 
highly conserved hexameric motif (KTKEGV), which is involved in the formation of 
amphipathic α-helices, similar to lipid-biding domain of apolipoprotein-like class A2 and 
its essential for membrane binding4,9,27. Several lines of evidence support the membrane-
binding capacity of the N-terminal region. For example, mutations in this region were 
show to perturb plasma membrane localization of the protein in yeast27.  
This portion of the protein includes the sites of five familial PD mutations: A30P, 
A53T, E46K and two new mutations discovered H50Q and G51D. Also, N-terminal 
acetylation is critical for forming α-helical oligomers thus suggesting that this event could 
have important implications for both the native and pathological structures of aSyn4,17,18,27 
(Fig.3).  
The central region comprises the NAC sequence which is highly hydrophobic and 
aggregation prone. This part of aSyn can undergo a conformational change from random 
coli to β-sheet structure. Moreover, it is able to form cylindrical β-sheets and amyloid-β-
like fibrils and protofibrils. The NAC region is indispensable for aSyn aggregation and 
toxicity; the deletion of large segments within this motif greatly diminished aSyn 
oligomerization and fibrillogenesis in vitro, and in a cell based-assay. Moreover, mutation 
of only one single amino acid in this central domain of aSyn can alter the aggregation 
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properties of the protein, emphasizing the importance of the NAC domain in the 
aggregation process4,22,25,27 (Fig.3).  
The last segment of aSyn, the C-terminal region (residue 96 to 140) is highly enriched 
in proline acidic residues and contains three highly conserved tyrosine residues (Y125; 
Y133; Y136) that are phosphorylation targets. The C-terminal is responsible for the 
intrinsically disordered nature of aSyn. This domain also plays a regulatory role in the 
aggregation and fibril formation of the protein, by shielding the hydrophobic NAC 
domain from the watery solution, in addition, the C-terminal appears to have chaperone 
activity4,22,25,27,28.  
 Deletion or modifications of C-terminal of aSyn, as well as changing the charge or 
hydrophobicity of the domain, enhances the aggregation rate of aSyn in vitro and in cells. 
For example, phosphorylation of Serine 129 (S129) or nitration of Y125, Y133 and Y136 
promote the formation of aSyn filaments or oligomers in the C-terminal half and enhance 
tendency to aggregate and fibrilize. These results suggest that the C-terminal can play a 
role of an intramolecular chaperone by preventing aSyn from fibrillization4,22,25,27,29.  
From these characteristics that we see above, it can be inferred that aSyn is a very 
versatile protein, as it can easily adopt different conformations upon interacting with 
biological membranes of different compositions, other proteins or protein complexes in 
physiological conditions9,22.  
 
Figure 3: Molecular structure and functional characteristic of aSyn. aSyn is functionally divided into 
N-terminal (1–60aa), NAC (61–95aa), and C-terminal (96–140aa) domains. The N-terminal domain 
contains four motifs (blue color) and has five point mutation sites linked to PD (A30P, E46K, H50Q, G51D 
and A53T) and also a tyrosine residue (Y39) which is a phosphorylation target. The NAC domain, which 
encompasses the most hydrophobic residues, promotes aggregation, with a phosphorylation site (S87). The 
C-terminal domain exhibits chaperone activity that tends to decrease protein aggregation, has one 
phosphorylation site (S129) and three tyrosine residues (Y125, Y133, Y136). (Adapted from25,27,28)  
 
 
YY125 Y133 Y136
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 Physiological function of Alpha-Synuclein 
 
Although aSyn is distributed to almost all subcellular compartments, it is particularly 
enriched in the presynaptic terminals where it is loosely associated with the distal reserve 
pool of synaptic vesicles. The high presynaptic concentration of aSyn, and its association 
with synaptic vesicles, suggest a physiological role of the protein in regulation of synaptic 
transmission as well as synaptic vesicle recycling22,25,27,29,30. 
Neurotransmitters are stored in vesicles after being synthesized. Those vesicles dock 
and fuse with the plasma membrane to release neurotransmitters into the synaptic cleft 
and then restock via recycling from the distal vesicle pool27,31. 
Overexpression, knockdown and knockout of aSyn lead to deficiencies in synaptic 
transmissions, supporting that it plays an important role in the regulation of 
neurotransmitter release, synaptic function and plasticity. For example, SNCA-knockout 
mice exhibit an impairment in hippocampal synaptic responses to prolonged trains of 
high-frequency stimulation that deplete the docked and reserve pool of synaptic 
vesicles22. Moreover depletion and suppression of aSyn induces an impairment of vesicle 
trafficking between the reserve pool and the ready releasable pool and a deficiency in the 
neurotransmitter uptake. Experiments with siRNA-mediated knockdown of aSyn resulted 
in significant decreases in Vmax for dopamine uptake and the surface density of dopamine 
transporter in SH-SY5Y cells. On the other hand transgenic mice overexpressing human 
aSyn display impairment in synaptic vesicle exocytosis and reduction in neurotransmitter 
release22,27. Another study in PC12 cell line show that overexpression of aSyn resulted in 
an accumulation of vesicles at the synapse22,27,31, and similar effects have been observed 
in genetic rodent models of PD27. In line with this studies overexpression of aSyn in yeast 
induces a block of the ER-to-Golgi vesicular traffic leading to defects in endocytosis and 
exocytosis4. 
  In transgenic mice, overexpression of aSyn was found to inhibit tyrosine hydroxylase 
(TH), the enzyme in charge for dopamine synthesis in dopaminergic neurons and 
consequently lead to a reduction on dopamine synthesis. In an opposite way down-
regulation of aSyn increase TH activity and DA synthesis27. 
The possible role of aSyn in regulating synaptic homeostasis is not exclusively related 
to its direct interaction with synaptic vesicles, because aSyn is able to interact with 
proteins that control synaptic vesicle exocytosis, such as phospholipase D2, the family of 
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RAB small GTPases, the synaptic protein synapsin 1 and soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE), which are crucial modulators of 
membrane trafficking, exocytosis and synaptic vesicle release in neuronal cells4,9. 
These data strongly indicate that aSyn displays an important role in the trafficking of 
synaptic vesicles and in the regulation of vesicle exocytosis and subsequently in 
neurotransmitter release4,22. Thereby, aSyn may contribute to a regulatory effect in the 
synaptic homeostasis and abnormalities in this regulatory function may influence the 
neurotransmitter release, leading to alterations on short-term and long-term synaptic 
plasticity4,22,27. 
 
 Alpha-Synuclein Aggregation 
 
The abnormal deposition of specific proteins in brain tissues is a feature of several 
age-related neurodegenerative diseases, including PD7. Several consequences are 
hypothesized to be associated with protein misfolding and aggregation: the loss of normal 
function; gain of toxic function, mechanical disruption of cellular compartments and 
processes such as synaptic, mitochondrial function and proteasomal activity12,23,32,33. The 
sequence of molecular events that lead to development of neurodegenerative diseases, 
implicates the accumulation of misfolded protein species, extending from oligomers to 
higher fibrilar protein aggregates (fig. 4), and once aggregated, these aggregates can grow 
and enlarge by recruitment of more misfolding proteins.  Accumulation of aggregated 
aSyn affects various functional structures of the nervous system leading to serious 
cognitive and behavioral alterations33. 
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The levels of aSyn in the CNS depend on the balance between the rates of aSyn 
synthesis, aggregation and clearance. Abnormal protein structure resulting from genetic 
alterations or overexpression of aSyn could create an imbalance between these 
mechanisms and will result in abnormal levels of aSyn that might benefit the formation 
and/or accumulation of oligomeric and fibrillar species, which will ultimately lead to the 
formation of large aggregates the LBs8,22,26.  For example, four missense mutations on the 
gene SNCA (A30P, E46K H50Q, and A53T) have been shown to accelerate aSyn 
aggregation compared to wild-type17,18,25,29. These higher rates of aggregation displayed 
by the mutant forms can be explained by changes in the structure of protein, because these 
mutations have the ability to disturb the α-helical structure of the protein in the N-terminal 
region, increasing the possibility of generating pathogenic conformation25,29. Many other 
factors and events have been reported to influence the aggregation of aSyn, such as: i) 
posttranslational modification of aSyn (phosphorylation; truncation). Phosphorylation of 
S129 promote the formation filaments and oligomers27,28;  ii) Incubation of aSyn protein 
with metals (cooper, iron) and pesticides (paraquat). In yeast, Fe3+ ions increase the 
Lewy Body 
Figure 4: aSyn aggregation. Schematic illustration of the process whereby normal soluble aSyn misfolds is converted 
into pathological oligomers and higher aggregates that fibrillize and deposit into Lewy bodies in affected neurons in PD 
brain.  
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number of cells containing aSyn inclusions34. Overexpression of aSyn in GT1-7 
hypothalamic cells generate aSyn inclusions like structures, and also alterations in 
mitochondria function, increasing the production of free radicals29.  
Another dysfunction associated with the aggregation of aSyn and its abnormal levels 
in the brain, is the impairment of the ubiquitin-proteosome system (UPS)7,8,35. The UPS 
is one important pathway for protecting cells against misfolded proteins, clearing 
misfolded proteins from the cytosol, endoplamatic reticulum and nucleus36. 
Overexpression of wild-type or mutant aSyn in cultures cells and in the brains of 
transgenic mice is known to impair UPS function. Proteossomal dysfunction and 
consequent accumulation of misfolded proteins may provoke a vicious cycle, which 
probably defies the capacity of the proteossomal clearance systems promoting 
accumulation and development of a self-propagating cycle7,33,35. When the misfolded 
aSyn begin to propagate and reach the acceptor cells, they begin to seeding the 
aggregation of endogenous protein in a prion–like fashion way37–39. This prion-like 
transmission of aSyn pathology relies on the premise that a sick neuron could release its 
misfolded aSyn to the extracellular space, or they gain access to the extracellular space 
when the neuron dies. Once out of the neuron the aSyn could be free to enter an adjacent 
neuron by endocytosis and act as a template, seeding the aggregation and initiating the 
formation of a LBs37. Studies with neuronal stem cells and embryonic neurons grafted 
into the brain of aSyn overexpressing transgenic mice can take up host aSyn and develop 
inclusions, supporting this theory40.  The accumulation of aggregated aSyn affects various 
functional structures of the nervous system leading to serious cognitive and behavioral 
alterations33.   
 
 Alpha-Synuclein Phosphorylation 
 
Posttranslational modifications (PTMs), such as phosphorylation, ubiquitination or 
sumoylation, which alter the protein size, charge, structure conformation and/or 
biological function, can also affect protein folding and aggregation, and thereby play a 
critical role in neurodegenerative disorders28,41. Beyond all this PTMs, protein 
phosphorylation is the most widespread type of modification used in signal transduction 
affecting every basic cellular process42. 
aSyn protein presents several phosphorylation sites (4 serine, 10 threonine, 4 tyrosine 
residues) that are highly conserved among numerous species. Nevertheless, 
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approximately 90 % of aSyn deposited in LBs is phosphorylated at S129. In contrast, only 
4 % or less of total aSyn is phosphorylated at this residue in normal brain, suggesting a 
close relationship between aSyn phosphorylation at S129 and its aggregation14,41,43–46. 
Several studies performed in cell lines associate aSyn phosphorylation with formation of 
oligomers, cytoplasmic and nuclei aggregates and cytoplasmic inclusions28, and in 
transgenic mouse models of PD, aSyn phosphorylation caused accelerated neuronal loss, 
suggesting a toxic effect of S129 phosphorylation21. Even so, some studies in yeast using 
a S129A mutation that blocks the phosphorylation in S129 residue, resulted in more toxic 
forms, and increased the number of inclusions and oligomeric species compared with the 
WT protein28. One hypothesis to explain this result lies in the fact that for some proteins 
phosphorylation acts as a signal for degradation by UPS and/ or autophagy. If this happens 
with aSyn protein, phosphorylated aSyn might accumulate in LBs due to proteosomal 
impairment leading to aggregation28,46. 
Multiple kinases have been implicated in aSyn phosphorylation, namely, G-protein 
coupled receptor kinases (GRK2, GRK3, GRK5 and GRK6), casein kinases 1 and 2 
(CK1, CK2) and Polo-like kinase 2 (PLK2) and PLK328,44,47. All these kinases could play 
an important role in the modulation of aSyn physiology.  For example, knockdowns of 
GKR3, GKR5 and GRK6 significantly decrease levels of aSyn phosphorylated at S12944. 
Overexpression of aSyn increased GRK5 protein expression in SH-SY5Y cells and in 
brain extracts of transgenic mice expressing human aSyn, additionally GRK5 was found 
to colocalize with aSyn in LBs of PD patients28. Another study showed that the 
overexpression of PLK2 is protective by mediating selective autophagy clearance of 
phosphorylated S129 aSyn48. This show that these kinases decide the fate of aSyn protein, 
thus, inhibition or overexpression of relevant kinases could be important in order to 
generate a potential therapeutic strategy28,43,48. Gathering all these data, it is clear that 
phosphorylation of aSyn is important in the context of its aggregation and toxicity, yet no 
conclusive agreement of this precise contribution this PTM has toward the disease 
process. For example, there is still no consensus on whether phosphorylation is neurotoxic 
or neuroprotective28. 
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 Mitochondrial Dysfunction and Oxidative Stress in PD 
 
Mitochondria, the power house of living cells and regulators of cell survival and death 
are especially complex and delicate organelles19. The first connection between 
Parkinson’s and mitochondria became apparent in the early 1980s with the discovery that 
a neurotoxin, MPTP (1- methyl-14-phenyl-1, 2, 3, 6-tetrahydropyridine) causing 
parkinsonian syndrome inhibits the mitochondrial respiratory complex I (NADH-quinone 
oxidoreductase)19,20,40,49. MPTP is converted to MPP+ by glial cells in brain and taken up 
by the dopamine transporter expressed in dopamine neurons. MPP+ is able to bind and 
inhibit mitochondrial complex I causing mitochondrial dysfunction and increasing the 
levels of ubiquitinydated proteins20,50. 
Consistent deficits in the subunits and activity of mitochondrial complex I of the 
electron transport chain in SNpc of PD patients is a prominent phenomenon. The activity 
of complex I has been reported to be reduced (in the range of 30%) in the CNS and frontal 
cortex of PD patients at autopsy. In mitochondrial preparations from PD frontal cortex 
samples, complex I subunits, derived from mitochondrial genome, were found to be 
oxidatively damaged15,40. Taking in to account this data, aSyn can be found in the 
mitochondria of the striatum and SNpc of PD patients contributing to impairing the 
complex I activity50. Moreover, in transgenic mouse models of aSyn overexpression, 
several mitochondrial anomalies were observed. These include oxidation of mitochondria 
associated proteins, mitochondrial DNA damage, increased oxidative stress, and 
bioenergetics defects40. Oxidative damage to mitochondrial DNA (mtDNA) may 
compromise encoding of respiratory chain subunits, thus initiating a vicious cycle of 
oxidative stress and bioenergetics failure49. Recently, it has been shown that the N-
terminal 32 amino acids of aSyn function as a targeting sequence for import aSyn into 
mitochondria20. This targeting sequence drives aSyn to the inner mitochondrial 
membrane  where it associates with complex I, leading to a decrease in its activity and 
increasing reactive oxygen species (ROS) production in human dopaminergic neuronal 
cultures overexpressing wild-type aSyn. In these models overexpression of A53T aSyn 
enhance these effects (Fig.5)19,49. ROS are chemically reactive molecules containing 
oxygen and are produced in all aerobic cells. Oxidative stress occurs when the generation 
of ROS overwhelms cells capacity (enzymatic and non-enzymatic antioxidants defenses) 
to scavenging them24. 
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In yeast cells expression of wild-type or A53T mutant aSyn accelerates apoptosis and 
ROS production. Remarkably these effects did not occur in yeast cells lacking mtDNA. 
Also, in other model C. elegans the overexpression of aSyn reduces the fusion rate of 
mitochondria40. At last, aSyn protofibrils are known to form annular pores in membranes, 
suggesting that permeabilization of mitochondrial membranes may be involved in aSyn 
toxicity20. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
As a consequence of impaired electron flux through complex I, mitochondrial ATP 
production decrease, creating a deficit of energy supply while the generation of ROS is 
increased24. Excessive production of ROS by mitochondria lead to impairment of cellular 
redox balance pushes the oxidation of biological macromolecules, such as DNA, proteins 
and lipids leading to failure of biological functions24,49. Another study in mice lacking 
aSyn presented resistance to MPTP, showing that aSyn is an essential mediator of the 
toxic effects of complex I inhibitors.  Remarkably, mitochondrial fragmentation another 
effect of overexpression of aSyn, can be prevented by PINK1, parkin, or DJ-1 but not by 
their pathogenic mutants, and the mitochondrial chaperone TRAP1 moderate the aSyn 
Outer menbrane permeabilzation 
α-syn 
ROS 
• PD mutations 
• aSyn overexpression 
• Ovidative Stress 
• Environmental factors 
aSyn aggregates and misfolded proteins 
Respitatory chain complex I 
Mitochondrial DNA 
Outer menbrane protein import channel 
Matrix Proteins ( Metabolism, translation) 
Dysfunctional mitochondria 
Figure 5: Effect of aSyn in mitochondria.  PD mutations; aSyn overexpression; oxidative stress and environmental factors 
are able to trigger aSyn aggregation and lead to mitochondrial dysfunction. Impairment of mitochondrial complex I activity 
by aSyn results in an increased production of ROS and promotes aSyn aggregation. Compromising mitochondrial function 
results in ATP deficits and ultimately will lead to a disruption of cellular homeostasis, abnormal protein aggregation and 
apoptosis. (adapted from reference20,49) 
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toxicity in cellular models, supporting the notion that aSyn affects mitochondrial 
function40. Taking in to account all the data above, the association of aSyn with 
mitochondria complex I raises the possibility that aSyn controls respiratory activity, and 
may mediate complex I inhibition generating mitochondrial alterations that will lead to 
an imbalance in cellular oxidative status inducing proteossomal deregulation. This may 
exacerbate protein aggregation and consequently degenerative events intensifying PD 
progression20,50. 
 
 aSyn the principal player in PD  
 
At largest level, aSyn and its abnormal accumulation in LBs is a key event in PD7. As 
seen aSyn is an extremely flexible protein that can adopt different conformations and 
interact with different types of membranes and proteins. aSyn accumulation, pathological 
modifications, aggregation and transmission can significantly impair synaptic functions 
causing defects in intracellular traffic and release of dopamine by dopaminergic neurons 
of the SNpc affecting memory and cognitive function4,7,51. Moreover elevated levels of 
aSyn overwhelm the ability of normal quality-control system to prevent or reverse protein 
misfolding or eliminate proteins that have assembled into pathological aggregates5. 
Mitochondrial dysfunction and oxidative stress are also characteristics of the abnormal 
expression and deposition of aSyn, causing deficits in ATP and may also promote 
misfolded protein conformations. The activation of the programmed cell death machinery 
are also believed to be factors that start the death of dopaminergic neurons in PD7,15. 
Together PD is an extremely complex neurodegenerative disease associated with different 
types of cellular dysfunctions. 
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  Polyphenols 
 
Polyphenolic compounds, or polyphenols, are secondary metabolites of plant 
metabolism and are widely distributed in the plant kingdom. Polyphenols are present in 
plants, fruits, and vegetables, including berries, olive oil, red wine, and tea52,53. They 
constitute a large group of phytochemicals with more than 8000 identified compounds. 
Examples of polyphenolic families include, stilbenes, coumarins, phenolic acids and 
lignans, being, flavonoids are the largest group of polyphenols53(Fig. 6). 
In terms of structure, phenolic compounds are characterized by the presence of at 
least one hydroxyl functional group (-OH) linked to a benzene ring. (Fig.6) For example, 
all flavonoids share a basic structure consisting of two or more benzene rings. 
The primary functions of these compounds are protection of plants against ROS, 
produced during photosynthesis52. Thus, phenolic compounds like flavonoids have the 
ability to quenching free radicals and interrupting the propagation of new free radical 
species54. In terms of consumption, the main dietary sources of polyphenols are fruits, 
vegetables and beverages, and the dietary intake of polyphenols has been estimated at 
about 1 g/day by Scalbert and Williamson55,56. Due to their biological properties including 
antioxidant, anti-inflammatory, antitumorigenic, antianxiety, anticarcinogenic, antiviral, 
anti-mutagenic and cardio-protective, polyphenols are currently receiving much attention, 
emerging as health promoting compounds55,56. Several pathways have been reported as 
being targets of phenolic compounds, thereby demonstrating the broad spectrum of 
targets and strengthening their usefulness in addressing multifactorial diseases52,57. 
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  Polyphenols in Neurodegeneration  
 
The pathogenesis of neurodegenerative diseases like PD is multifactorial with a 
complex combination of genetic and non-genetic components. Oxidative damage to 
neuronal cells, accumulation of iron species in the brain, and reduced or depletion of 
endogenous antioxidants are examples of pathological aspects of neurodegenerative 
disorders. Oxidative stress has been related to be an important pathogenic mechanism of 
neuronal apoptosis in PD58. Whereas there is an imbalance in the production of ROS in 
PD, polyphenols appear as compounds with therapeutic potential, since they are capable 
scavenge free-radicals in studies in vitro52,59,60. The neuroprotective effects of many 
polyphenols and their metabolites rely on their ability to scavenge pathological 
concentration of ROS and nitrogen species and chelate transition metal ions, breaking the 
vicious cycle of oxidative stress and tissue damage61. For instance, flavonoids, more 
Polyphenols
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Figure 6: Classification and chemical structures of the main dietary polyphenols classes 
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precisely catechins and their derivatives, such as (-)-epigallocatechin-3-gallate (EGCG), 
prevented dopaminergic neurons injury induced by the neurotoxin MPTP in mice. In 
addition, EGCG protect cells against 6-hydroxydopamine (6-OHDA), a dopaminergic 
and adrenergic neurotoxin53. Moreover, EGCG and quercetin reversed ER-to-Golgi 
trafficking defects and mitochondrial dysfunction, in yeast, whereas quercetin also 
showed protective effect in PC12 cells exposed to H2O2. Also resveratrol protects neurons 
against radical overloading and prevents accumulation of ROS52,62. Additionally 
dopaminergic neurons were protected against MPTP when mice received Ginkgo biloba 
two weeks before the neurotoxin been infused53. 
Besides, emerging evidence suggests that the scavenging activity of polyphenols 
cannot be the only mechanism responsible for their neuroprotective effect, the cellular 
effects of polyphenols also may be mediated by their interactions with specific proteins 
central to intracellular signaling pathways, such as MAPK and PI3K/Akt cascades, which 
regulate pro-survival transcription factor and gene expression53,57,59. For instance, in vitro 
studies demonstrate that EGCG could induce MAPKs pathways including extracellular 
signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK) and p3853,57. Activation of 
ERK is generally pro-survival, while inhibition of c-jun and p38 pathways are also likely 
to be neuroprotective57. It has been indicated that flavonoids are able to block the 
oxidative stress induced activation of caspase-3 in neurons, via a mechanism involving 
the suppression of the JNK pathway and downstream partners, supporting the anti-
apoptotic action of flavonoids53,57,63.   
There is also data suggesting that fruit and vegetable derived polyphenols are 
capable of promoting beneficial effects on memory, learning and cognitive performance 
through their ability to exert effects directly on the brain’s architecture for memory53,57,63. 
Fisetin, a flavonoid found in strawberries, has been show to improve long-term 
potentiation and enhance object recognition in mice by a mechanism dependent on the 
activation of ERK and the cAMP response element-binding protein (CREB)57,63. Equally, 
the flavonol (-)-epicatechin (EC) induces activation of ERK and CREB in cortical 
neurons, increasing CREB regulated gene expression57,59,63. CREB is a critical 
transcription factor in the activation of neurotrophins such as brain-derived neurotrophic 
factor (BDNF), that promote neuronal survival, differentiation, synaptic function and 
memory57,63.  
The emerging observation is that the intake of polyphenol rich foods, such berries, 
throughout life holds a potential to limit neurodegeneration or reverse cognitive 
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performance impairments. Polyphenolic compounds could exert beneficial effects on 
cells through the modulation of different pathways such signaling cascades and anti-
apoptotic processes. However, in vivo studies are needed to clarify whether sufficient 
concentrations of polyphenols, reaches the brain, and alters cell signaling pathways53,63. 
 
 
 The Awesome power of the Yeast tool 
 
The yeast Saccharomyces cerevisiae, also known as baker’s or budding yeast, is 
the most extensively studied eukaryotic organism and has been used as a biotechnological 
tool for many centuries. Yeast cells are widely used as model organism because basic 
cellular mechanisms, such as cell division, DNA replication, metabolism, protein folding, 
membrane trafficking and protein quality control mechanisms are well conserved 
between yeast and higher eukaryotes, including mammals10,64. Yeast cells exhibit several 
characteristics that make it an incredibly useful model for genetic and biochemical 
approaches. These includes simple manipulation and screen for induced phenotypes, 
rapid growth on defined media with a doubling time of approximately 90 min. Survives 
indefinitely in frozen glycerol stocks, inexpensive when compared with other eukaryotes, 
easy replica plating, and the most important, highly versatile DNA transformation and the 
ability to integrate genes by homologous recombination10,64,65. As result of the advantages 
described above, S. cerevisiae was the first eukaryote organism to be fully sequenced in 
1996 and of the 6000 genes predicted to be encoded by its 12000 kb genome, 
approximately 80% are functionally characterized65. Altogether, these qualities make the 
yeast an attractive model to modeling and study human brain disorders, for example10,66. 
Two different strategies can be implemented when modeling a human disease in yeast. If 
the gene implicated in the disease has a yeast homolog, it is possible to study its function 
directly. If on the other hand, the gene underlying the disease is absent in yeast, it can still 
be modeled via the heterologous expression of the human gene in yeast cells10. As it 
happens with PD and other neurodegenerative diseases for example30. 
Despite all the potential of yeast, biological pathways and mechanisms present in 
higher eukaryotes are absent in yeast and, on the other hand, some pathways, such cell 
wall biosynthesis, have no counterpart in mammals. Therefore, all findings in yeast 
related to human diseases must ultimately be validated in more physiologically relevant 
systems prior to their trial in humans64,65. 
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 Parkinson’s disease Yeast Model 
 
Regardless of its limitations as a unicellular eukaryote, yeast expressing aSyn can 
faithfully reproduce key features of PD pathology. Since the initial description of the first 
yeast model of PD by Outeiro & Lindquist in 200330, other groups have taken advantages 
of the potential that the yeast model offers to study PD related features. One example, are 
the yeast strains carrying the galactose-inducible aSyn constructs, where aSyn is 
expressed under the control of a galactose-inducible promoter. (Fig. 7) 
Several characteristics of PD can be reproduced in yeast based on the heterologous 
expression of human wild-type aSyn and clinical mutants. Accordingly studies using this 
models linked the formation of aSyn aggregates directly to toxicity. In addition, the 
expression of aSyn wild-type and the mutant A53T inhibits growth and promote cell death 
in a concentration-dependent manner10. These observation are reviewed in other models 
such as rat primary mesencephalic cultures and Drosophila.  Furthermore the impairment 
of vesicular trafficking, endocytosis and vacuolar degradation are also effects of aSyn on 
yeast10,67. The ER-to-Golgi transport and secretory pathway are blocked and impairment 
in UPS system is also reported models expressing aSyn. Treatment with ferrous ions 
triggered an increase in oxidative stress associated with enhanced inclusion formation and 
toxicity of aSyn. Yeast was also used for drug screens in order to identify several 
therapeutic compounds that rescue aSyn toxicity10,34.Namely, the flavonoids, quercetin 
and (-)-EGCG, were found to counteract aSyn toxicity, reducing damage to 
mitochondria10,34,52,58,63. Collectively, these data reveal a phenotype based yeast model 
that recapitulates pathological properties of human aSyn34. In conclusion, it is clear that 
yeast represents a valuable cellular tool decipher the devastating pathological role of aSyn 
in PD10,65,67. 
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 Proteomics approaches 
 
Proteomics seeks to study all proteins expressed in any given organism, whether 
by abundance, activity, structure, posttranslational state or other modification, protein 
interaction with each other in complexes and signaling pathways. Several technologies 
can be used in the proteomic research. For example with the introduction of two-
dimensional gel electrophoresis (2-DGE) in the 70s made it possible to obtain a picture 
of the cellular protein content, the proteome68,69. The proteome is defined as the set of 
proteins expressed from the genome of an organism at a given time under defined 
conditions. Generally, the proteome is modified according to the specific biological and 
pathophysiological state of the organism70. 
Proteome analysis are carried out by combining techniques of protein separation 
and identification. Among the proteomic tools, can be highlight the electrophoretic 
techniques, and in terms of identification, stands out mass spectrometry (MS) as 
technique of choice. 2-DGE is a powerful separation technique which allows 
simultaneous resolution of hundreds or even thousands of proteins.  
This technique separates proteins by their isoelectric point (pI), that corresponds 
to the specific pH which the net charge of the proteins is zero, through an immobilized 
pH-gradient (IPG) gel matrix in the first dimension, and then by molecular weight (mW), 
the second dimension70–73. Visualization of proteins in gels is accomplished with staining 
techniques. Colloidal Coomassie blue and zinc are examples of stains for the visible 
Figure 7: Example of Yeast Construction to study PD related features. Yeast model carrying two integrative 
plasmids, containing two copies of SNCA gene (aSyn) with a galactose inducible promoter and auxotrophic 
markers URA3 and TRP1 respectively, which by homologous recombination are integrated into the host genome. 
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range, in terms of fluorescence staining SPYRO ruby is an option. Each technique 
presents specific aspects, sensitivity, and reproducibility. Protein stains must be 
compatible with MS72,73. Gel images can be examined visually, but objective spot 
detection, quantification and comparison of a large number of protein spots require a 
computer support, through the use of specific image analysis software that allows a 
precise examination of the proteome72. Image-analysis software also guides the excision 
of proteins from gels for further analysis and characterization. 
There has been rapid growth over the last decade in the field of proteomic, strongly 
motivated by improvements in MS and informatics platforms. Without doubt, proteomics 
has already provided significant insights into biological function of proteins and this will 
carry on as the technology continues to improve, the ultimate goal, is to obtain full 
coverage of all proteins in proteome-wide studies, allowing a complete separation and 
characterization of all protein species present in a given organism69,71,72. 
 
 Phosphoproteomics 
 
Protein phosphorylation is the most widespread and diverse of the PTMs found in 
nature, playing a crucial role in the regulation of many biological functions in prokaryotic 
and eukaryotic cells74–76. Phosphorylation and dephosphorylation on serine, theorine, and 
tyrosine residues are the key regulators of cellular signaling pathways, which are involved 
in most of cellular events and biological process, like protein synthesis, gene expression, 
cell survival and apoptosis74,76. Phosphorylation affects protein structure by changing the 
charge and hydrophobicity, thus, conformational changes can be induced, affecting the 
properties of the protein, leading to activation, deactivation, or change in protein 
interaction partners75,76. It has been reported that up to 50% of all proteins may be 
phosphorylated during lifetime, and over 100 000 potential sites of phosphorylation exist 
in the human proteome75. 
Thereby, analysis of phosphoproteomes and its alterations is increasing and 
gaining more attention among researchers.74 In order to respond to this increased interest 
in the study of phosphorylation, phosphoproteomics, appears as an emerging field. With 
the aim of characterizing phosphoproteins and phosphorylation sites, mapping 
phosphorylation networks and understand protein phosphorylation events controlling 
various cellular processes74. One of advances in this area is the development of a unique 
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fluorescence stain, Pro-Q Diamond phosphoprotein stain (Pro-Q DPS)77,78. Specific for 
phosphoproteins, Pro-Q DPS made possible the selective detection and quantification of 
the phosphoproteome, following separation by 2-DGE71,77. Pro-Q DPS binds directly and 
specifically to the phosphate moiety of phosphoproteins independently of which amino 
acid residue is phosphorylated and is compatible with other stains, such as glycoprotein 
and total protein stains and MS71,75–77. For example, a combination of Pro-Q DPS and 
SPYRO ruby or CCB for staining all proteins in the same 2-DGE can be apply. This 
approach allows the quantitative detection of different classes of proteins in 2-DE gels71. 
Since the deregulation in phosphorylation is a characteristic of some neurodegenerative 
diseases, such as PD and AD, thus phosphoproteomics might be the technique of choice 
to unravel the protein’s phosphorylation and interaction in networks both in normal and 
diseased state74,75. 
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Materials and Methods 
 Plant Material 
 
Leaves from C. album (Corema album (L.) D. Don) were selected for this study. 
Leaves, collected by random sampling in Comporta (southern region of Portugal), were 
frozen in liquid nitrogen and stored at -80 ºC. Before utilization the samples were ground, 
freeze-dried and subsequently stored at -20 ºC. 
 
 Extract Preparation 
 
Secondary metabolites were extracted from C. album leaves using clean solvents, as 
previously described by Tavares and co-workers79. Briefly, to 1 g of fresh weight plant 
material, 6 ml of hydroethanolic solvent 50 % (v/v) (ethanol/water) were added. The 
mixture was shaken for 30 min at room temperature in the dark and then centrifuged at 
12400 g for 10 min at room temperature. The supernatant was first filtered through a 
paper filter and then trough a 0.2 μm cellulose acetate membrane filter. The resulting 
extracts were freeze-dried and stored at -20 ºC. 
 
 Extract Fractionation 
 
The hydroethanolic extracts were fractioned by solid phase extraction (SPE) using 
Giga tubes 2g/12mL, C18-E units (Phenomenex®), according to Tavares and co-
workers79. This procedure allows the removal of interfering molecules like organic acids, 
sugars and to concentrate into a polyphenol enriched fraction (PEF)  Briefly, the column 
was first equilibrated with acetic acid (Panreac; Spain) in water 0.5 % (v/v) 
(CH3COOH/H2O) and the dried extracts were ressuspended in the same equilibration 
solution, before being applied to the columns. The unbound material, which contained 
interfering molecules, was washed out using two volumes of the same solution. Finally, 
the bound fraction, that is enriched in polyphenols, was eluted with a solution of acetic 
acid in acetonitrile (Riedel-de Haën®; USA) 0.5 % (v/v) (CH3COOH/CH3CN). Fractions 
were concentrated in a Spped-Vac (Labconco, USA) and stored at -80 ºC. 
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 Measurement of Total Phenol Content 
 
Determination of total phenolic compounds was performed by the Folin-Ciocalteau 
method, adapted to a 96 microplate reader, as described by Tavares and co-workers79. 
Briefly, to each well of a microplate, 235 μL water, 5 μL sample, 15 μL Folin-Ciocalteau 
reagent (Fluka®; USA) and 45 μL saturated Na2CO3 (Riedel-deHaën®; USA) were 
added. The microplate was incubated for 30 min at 40 ºC and the absorbance at 765 nm 
was measured. Gallic acid was used as the standard and the results were expressed in mg 
of gallic acid equivalents per gram of dry weight (mg GAE g-1 dw) of plant material. All 
measurements were performed with three replicates. 
 
 Yeast strains 
 
In this study Saccharomyces cerevisiae was used as a model organism. The selected 
strains were aSyn-1, aSyn-2 (MAT alpha can1-100 his3-11 15 leu2-3 112 ade2-1 
GAL1pr-syn WT::TRP1; GAL1pr-syn WT::URA3) and Control strain (MAT alpha can1-
100 his3-11 15 leu2-3 112 ade2-1 TRP1 URA3)  encoding two copies of aSyn the 
hallmark protein of Parkinson disease, under the control of a galactose inducible promoter 
and the respective empty vectors, respectively. These strains were isogenic to W303 
(MAT alpha can1-100 his3-11 15 leu2-3 112 ade2-1). 
 
 Media and growth conditions 
 
The strains were grown and maintained on YPD (Yeast extract, Peptone, Dextrose) 
solid medium [1 % (w/v) yeast extract (HiMedia; India), 2 % (w/v) glucose (Sigma 
Aldrich; USA), 2 % (w/v) peptone (HiMedia) and 2 % (w/v) agar (HiMedia)] at 4 ºC, 
after growth at 30 ºC for 48 hours. For long term storage, YPD cultures containing 50 % 
(v/v) glycerol were frozen at -80 ºC.  
For all experiments, an overnight pre-inoculum was prepared in synthetic complete 
(SC) liquid media [CSM (complete supplement mixture) 0.79 g.L-1 (QBiogene), 0.67 % 
(w/v) YNB (yeast nitrogen base) (Difco; USA) and 1 % (w/v) raffinose (Sigma Aldrich, 
USA)]. Subsequently, yeast cultures were diluted in the same medium, in order to 
synchronize the cultures and grown overnight at the same conditions until a final optical 
density at 600 nm (OD600 nm) of 0.7-0.8 ± 0.1. Cells were diluted to a final OD600 nm of 0.2 
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in SC liquid medium supplemented with 2 % (w/v) galactose (Sigma Aldrich) 
supplemented or not with C. album leaf PEF and grown under agitation during 6 hours at 
30 º C. After this period yeast cell cultures were ready for the subsequent analysis. Cell 
density of cultures was measured using the plate spectrophotometer Power Wave XS 
(Biotek®). 
 
 Growth Curves 
 
aSyn cytotoxicity as well PEF toxicity and cytoprotection was evaluated by means of 
growth curves.  After inoculum preparation and 6 hours of induction with 2 % (w/v) 
galactose or 2 % (w/v) glucose (Sigma Aldrich, USA), cells were diluted in the same 
media to a final OD600 nm of 0.03 in a 96 well plate supplemented or not with C. album 
leaf PEF to a final volume of 100 μL. For PEF toxicity and protection evaluation, were 
used several concentrations of PEF (0, 15, 30, 62.5, 125, 500 μg GAE. mL-1).  
The cultures were incubated at 30 ºC for 24 hours, with constant shaking and yeast 
growth was kinetically monitored hourly by OD600 nm readings. All experiments were 
performed with three biological replicates.  
 
 Phenotypic Growth Assays  
 
 In a 96-well plate, cells were diluted to an OD600 nm of 0.2 in SC liquid medium 
containing 2 % (w/v) galactose or 2 % (w/v) glucose and supplemented with C. album 
leaf PEF (0, 15, 30, 62.5, 125, 500 μg GAE.mL -1). The microplate was incubated during 
6 hours at 30 ºC, with constant shaking.  Subsequently, 30 μL of yeast cells were 
withdrawn to a new 96-well plate and the OD600 nm was adjusted to 0.1 with PBS 
(phosphate buffer saline) pH 7.4. Finally, a four-fold serial dilutions were made in PBS 
pH 7.4 and 5 μL was spotted onto galactose and glucose supplemented solid medium, 
plates were incubated for 48 hours at 30 ºC. Experiments were perform with at least three 
biological replicates. Images were acquired using Quantity-one® software from 
Chemidoc and obtained in the end of 48 hours of growth. 
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 Protein extraction 
 
Cells were diluted to a final OD600 nm of 0.2 in SC liquid medium with galactose 2 % 
(w/v) supplemented or not with 30 μg GAE.mL -1 of C. album leaf PEF and grown as 
described in section 2.6. Cells were harvested by centrifugation (2500 g for 5 min at 4 
ºC), washed with PBS and cell pellets were immediately stored at -80 ºC. Protein 
extraction was performed according to Santos et al66.  Briefly, cell pellets were thawed 
on ice and ressuspended in lysis buffer [Tris-HCl 25 mM, pH 7.4 (Carl Roth®; Germany) 
supplemented with 1 % (v/v) cocktail inhibitor proteases III (Merk Milipore; USA)]. Cell 
lysis was carried out with six consecutive steps of vortexing and ice cooling with glass 
beads (425–600μm) (Sigma Aldrich, USA). The mixture was centrifuged at 15,300 g at 
4 ºC for 5 min, the supernatant was collected and the pellet was ressuspended in lysis 
buffer. The mixture were centrifuged in the same condition, the supernatant collected was 
mixed with former. The mixture was clarified by centrifugation at 15,300 g at 4 ºC for 10 
min.  
 
 Protein Quantification 
 
Protein quantification was performed using a modified Lowry’s method as reported 
by Bensadoun and Weinstein80. The original method has been modified so that proteins 
can be assayed in the presence of interfering chemicals such as Tris or ammonium 
sulphate. The absorbance of the samples was measured at 750 nm80,81. 
 
 SDS-PAGE 
 
Ten μg of protein  were subjected to SDS-PAGE in 10 % (w/v) acrylamide gels with 
1 mm thickness at 200 V during 1 hour in electrophoresis buffer [25 mM  Tris base (Carl 
Roth®), 192 mM glycine (Carl Roth®) and 0.1 % SDS (Merk Milipore)].  The Protein 
Marker VI (AppliChem®; Germany) was run along with the samples. 
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 Western Blot 
  
The electrotransfer of polypeptides was done according to Swerdlow et al.82. After 
SDS-PAGE, gels were incubated in electrotransfer buffer [25 mM  Tris base, 19 mM 
glycine, 0.1 % (w/v) SDS and 20 % (v/v) methanol pH 8.3] during 15 min. PVDF 
membranes (Amersham Biosciences, Sweden) were incubated in methanol followed by 
incubation in electrotransfer buffer. The gel and the membrane were assembled in transfer 
cell (Trans-Blot electrophoretic transfer cell, BioRad, Amadora, Portugal) containing 
transfer buffer. Transfer was carried out at 70 V for 1.5 hours at 4 ºC. 
 
 Immunodetection 
 
After protein transfer, membranes were dried at room temperature and blocked with 
TBS-Tween-MBA [5 % (w/v) membrane blocking agent (MBA; GE Healthcare®), 
prepared in Tris-Hcl 1.5M pH 7.8, and Tween 20® (TBS-Tween)] for 30 min with 
agitation at room temperature. The membranes were first incubated with the primary 
antibody anti-aSyn (C-20)-R (1:500) (Santa Cruz Biotechnology, USA) in TBS-Tween-
MBA overnight at 4 ºC. The membranes were then washed three times for 5 min in TBS-
Tween followed by incubation with secondary antibody Goat anti-Rabbit (1:300) 
(Milipore) in TBS-Tween-MBA for 2 hours at room temperature. For loading control, the 
membranes were incubated with primary antibody PGK (1:3000) (Life technologies) in 
TBS-Tween-MBA for 2 hours and after three washes of 5 min in TBS-Tween the 
membranes were incubated with secondary antibody goat anti- Mouse HRP conjugated 
(1:5000) (Pierce) in TBS-Tween-MBA for 2 hours at room temperature. All incubation 
were performed with constant orbital agitation. Antibody detection was performed with 
chemiluminescent substrate (FemtoMax Super Sensitive Chemiluminescent HRP 
Substrate, Rockland Inc., Gilbertsville, USA). Images were acquired using the Molecular 
Imager ChemiDoc XRS (Quantity One© software v. 4.6.6; BioRad, Amadora, Portugal). 
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 Sample preparation for Two-Dimensional Electrophoresis 
 
Before 2D SDS-PAGE analyses cell extracts were subjected to a cleaning process 
using the 2D Clean-Up kit® (GE Healthcare®; Sweden) according to the manufactures 
instructions.  This kit is designed to clean samples from impurities such as nucleic acids, 
lipids and salts that would otherwise produce poor 2-D results due high levels of 
interfering substances or low concentration of proteins. After the cleaning process, 
protein pellets were resuspended in ressuspension buffer [7 M Urea (Carl Roth®), 2 M 
Thiourea (Sigma Aldrich), 4 % (w/v) CHAPS ( Merk Milipore), 2 % (v/v) IPG Buffer 
(1:2, 3-10 NL:4-7L) (GE Healthcare®), 1 mg. mL-1  DNase (Merk Milipore), 60 mM DTT 
(Carl Roth®), 1 % (v/v) cocktail inhibitor proteases III] and stored at -20 ºC until further 
use. 
 
 Two-Dimensional Gel Electrophoresis 
 
 The isoelectric focusing electrophoresis (IEF) was performed according to Santos et 
al.66 using the IPGphor™ system (GE Healthcare®) and IPG strips with non-linear 
gradient gel of pH 3-10, 13 cm (IPG strips Immobiline DryStrips, GE Healthcare®). 
Briefly, the samples containing 75 μg of protein were centrifuged at 13,400 g at room 
temperature during 5 min and the supernatant was applied to the Strip Holder. The IEF 
was carried out at the following conditions: 30V for 12 hours, followed by 250V for 1 
hour, 500 V for 1.5 hours, 1000V for 1.5 hours, 2500 V for 1.5 hours, 8000V for 1 hour 
gradient and 8000V for 4 hours at 20 ºC. At the end of the IEF the strips were stored at  
-20 ºC until second dimension separation was performed66. 
Prior to SDS-PAGE, the IPG Strips were equilibrated in two sequential incubations 
of 15 min in buffer solution [50 mM Tris-HCl (pH 8.8), 6 M urea, 2 % (w/v) SDS, and 
30 % (v/v) glycerol (Sigma Aldrich)]. DTT at a concentration of 0.06 mM was added to 
first the equilibration solution and 0.135 mM iodoacetamide (Sigma Aldrich) to the 
second one. The equilibrated strips where subjected to SDS-PAGE in 12.5 % (v/v) 
acrylamide gels with 1 mm thick. Protein standards (PeppermintStick™ Phosphoprotein 
molecular weight; Molecular Probes®, USA) were run along with sample at 15 mA per 
gel for 15 min and then 30 mA per gel for 4 hours.  
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 Pro-Q® Diamond 
 
For phosphoprotein detection, after electrophoresis, protein polypeptides/spots were 
stained with Pro-Q® Diamond phosphoprotein gel stain (Molecular Probes®; USA) 
according to Santos et al66. Briefly, the gels were placed in a fixing solution [50 % (v/v) 
methanol (Carlo Erba Reagents) and 10 % (v/v) acetic acid] overnight with orbital 
agitation. After the fixation step, the gels were washed three times with ultra-pure water 
for 15 min and were incubated with Pro-Q® Diamond solution for 2 hours in the dark with 
orbital agitation. After this period, the gels were incubated for 30 min in a solution 
containing 20 % (v/v) acetonitrile and 50 mM sodium acetate pH 4 (Riedel-de Haën®). 
This step was repeated twice and were followed by three washes for 5 min in ultra-pure 
water, the gels were immediately scanned in a laser imager with 532-nm excitation and 
580 bandpass emission filter FLA-5100 Fuji Photo Film Co, Ltd.  
 
 
 Commassie Brilliant Blue G 
 
For total protein detection Commassie Brilliant Blue G (Amersham Biosciences, 
Sweden) was used. Staining was done according to Neuroff et al.83. Briefly, the gels were 
incubated first in a solution containing 34% (v/v) methanol, 17% (w/v) ammonium 
sulphate (VWR) and 2% (v/v) of phosphoric acid (Carl Roth®) during 1 hour. After this 
period, a solution containing 1.1% (w/v) Commassie Brilliant Blue G and 34% (v/v) 
methanol was added and gels stayed in this solution for 48 hours with orbital agitation. 
Before image acquisition the gels were washed three times for 15 minutes. Gel images 
were acquired by the Image Scanner (Amersham Biosciences, Sweden).  
 
 2D Gel Analysis 
 
For spot detection, measurement and matching, gel images were analyzed in 
Progenesis SameSpots software (Nolinear Dynamics, Newcastle, United Kingdom). The 
first step in the analysis was image control. Images went through a process of image 
quality assessment for accurate image analysis. The next step was to select a suitable 
reference image to align all the images and then the areas of the gel to be excluded from 
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the analysis were defined. Once made the detection of spots they were edited, validated 
and reviewed. One of the crucial steps in this analysis is spot volume normalization: the 
intensity of each spot in gel is expressed as a proportion of the total protein intensity 
detected in the entire gel. Individual spots with irregularities (i.e. Ink spikes) were 
rejected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: Phosphoproteome alterations    
34 
 
Results and discussion  
 Establishment of the Yeast model of PD 
 Growth curves  
 
Saccahoromyces cerevisiae strains that were selected for this study are isogenic 
to W303 (MAT alpha can1-100 his3-11 15 leu2-3 112 ade2-1). The aSyn-1 and aSyn-2, 
that were tested are both with the same genotype (MAT alpha can1-100 his3-11 15 leu2-
3 112 ade2-1 GAL1pr-syn WT::TRP1 GAL1pr-syn WT::URA3), encoding two copies of 
SNCA gene (aSyn) under the control of a galactose inducible promoter and finally, the 
control strain (can1-100 his3-11 15 leu2-3 112 pRS304::TRP1 pRS306::URA3 ade2-1).  
These strains were used to evaluate the effect of aSyn expression in cell phenotype.   
The most common method to study cell growth is through batch culture, in liquid 
medium, allowing the monitorization of yeast growth and the detection of phenotypic 
changes or growth defects based on the genetic mutation presents in strains.  In a classic 
cell growth analysis in liquid medium, the number of yeast cells in a growing population 
is monitored by the optical density at 600 nm (OD 600 nm) and pertinent growth parameters, 
such as Lag phase time, doubling time (DT) and final biomass are extrapolated from the 
growth curve. Lag phase time is determined based on the linear regression of log growth 
phase equation obtained after logarithmic transformation of OD600 nm values, and 
corresponds to the time required by cells to respond to environment changes. The DT is 
also obtained based on the logarithmic transformation of OD600 nm values. DT can be used 
to characterize the kinetic growth of a population and is an indicator of the microorganism 
response to a specific condition. Growth rate varies typically with the strain and is deeply 
influenced by the growth medium, being obviously higher under an optimal growth 
environment. The rate of growth together with stationary-phase OD increments reflects 
quantitatively the minor changes in growth phenotype and is show by cell density or final 
biomass in the end of growth10,84,85. 
In order to determine growth curves and parameters of yeast expressing or not 
aSyn, as a first approach in this optimization, yeast cells of each strain were grown in SC 
medium with glucose (aSyn “off”) or galactose (aSyn “on”) as described in sections 
(Media and growth conditions; Growth curves) in material and methods. The SNCA gene 
is under the control of a galactose promoter, which is regulated by the carbon source 
present in the growth media. Thus glucose represses expression of aSyn, and galactose 
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allows the expression of aSyn protein. The growth was monitored hourly during 24 h 
(Fig. 8a, b).  
 
Figure 8: Growth Curves and growth parameters of S. cerevisiae strains expressing or not aSyn. 
S. cerevisiae strains Control (♦); aSyn-1 (●); aSyn-2 (×) were grown in SC liquid medium with a) glucose 
or b) galactose for 24h at 30ºC. a) and b) Grown was kinetically monitored hourly by OD measurements 
at 600 nm and growth curve represented. c); d); e) Growth parameters were determined based on the growth 
curve, c) doubling time, representing the time necessary to cells to duplicate, determined by logarithmic 
transformation of raw OD 600nm from growth curves. d) Lag time, representing the adaptation time, 
determined by logarithmic transformation of raw OD 600nm from growth curves. e) Final Biomass (OD 
600nm), representing the final OD of each culture, is calculated based on the measurements of OD at 24 
hours of growth. Results represent the mean ± SD of three independent biologic replicates. *** indicate 
statistically significance between Control, aSyn-1 and aSyn-2, for a p<0.001 respectively.  
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The results of growth curves (Fig 8a, b) show that the three strains, control; aSyn-1; 
aSyn-2, grew equally in medium with glucose as carbon source as expected (Fig 8a). On 
the other hand, yeast strains aSyn-1 and aSyn-2 show a decrease in growth compared to 
control strain, when grown in medium containing galactose as carbons source (Fig. 8b). 
This is due to the fact that aSyn expression is toxic to cells. The aSyn protein is the main 
component of Lewys bodies, the pathological hallmark of PD. This is the first effect of 
the expression of aSyn protein, leading to a reduction in growth rate, compared with the 
control strain (Fig. 8b).  
Nevertheless, aSyn-2 displays a lower growth rate when compared to aSyn-1(Fig. 
8b). It was noted that aSyn-1 and aSyn-2 display a much higher doubling time when 
compared with empty strain in medium with galactose (Fig. 8c). In contrast, in medium 
with glucose, where there is no expression of aSyn protein, the DT of all the strains are 
quite similar (Fig. 8c). Consistent with these results, the lag time of aSyn-1 and -2 are 
greatly higher compared with the empty in galactose. As expected in glucose the lag times 
are identical (Fig. 8d).   
Finally, in terms of final biomass, it is possible to observe that control cells exhibit 
similar growth on both glucose and galactose medium. The same is not true for aSyn-1 
and -2, since we found that this two strains have a lower final biomass in SC medium 
with galactose, compared with growth on glucose (Fig. 8e). Looking at the data of the 
growth curves and growth parameters, it was determined that aSyn-2 reveals a DT and a 
lag time higher compared to aSyn-1 (Fig. 8c, d).  
Globally, the results observed reflect the toxicity of aSyn for yeast cells and are 
in agreement with what was previously reported (Outeiro and Lindquist, 2003). 
Moreover, the results show that aSyn-2 strain is more sensitive to the toxic effects of aSyn 
expression than aSyn-1 strain. Thus, this strain was selected for the further studies. 
Nevertheless, these results indicate a toxic effect associated with the expression of aSyn 
protein, which is reflected in the final biomass, lag time and DT of cells.  
Also, the optimal galactose concentration to induce aSyn expression in our yeast 
cells were accessed by immunoblotting, as shown in annex 1. 
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  Effects of polyphenols on yeast growth 
 
Phytochemicals are known for their antioxidant activities and, among these, 
polyphenols are recognised for their neuroprotective effects. These phytochemicals occur 
naturally in plants and current evidence strongly supports a contribution of polyphenols 
to the prevention of several diseases like cardiovascular diseases, cancer, and 
osteoporosis. 
In this work it was analysed the effect exerted by polyphenol enriched fraction 
(PEF) from leaves of Corema album in yeast cells expressing aSyn protein.  
Corema album (L.) D. Don, 
belong to Empetraceae family, also 
known as Portuguese crowberry (Fig. 
9), is a dioecious shrub endemic from 
Iberian Peninsula and Azores Islands 
that grows in sandy dunes and coastal 
cliffs of the Atlantic coast. It produces 
edible berries, which look like little 
pearls. This fruit is not currently 
commercially explored and very few 
studies were performed, still this plant can be a potential source of phytochemicals.  
Leaves were used in this study, based on previously data obtained by DSB lab 
(unpublished data), indicating that the leaves reduced the percentage of yeast cells 
displaying aSyn inclusions compared with other matrixes, such as fruit.  
After collected the plants, the next objective was to obtain the polyphenol enriched 
fractions from the leaves, in which the total content of these metabolites is concentrated. 
Solid phase extraction with C18-E columns was used for this purpose (section Extract 
Preparation in material and methods) allowing also the removal of organic acids, sugars 
and minerals that otherwise could interfere with the following analysis. After this 
concentration step, the total phenolic content of several fractions was estimated by Folin-
Ciocalteau method (section Measurement of Total Phenol content in material and 
methods). Therefore, control and aSyn-2 yeast cells were incubated with several 
concentrations of C.album leaf PEF (0, 15, 30, 62.5, 125, 500 μg GAE.mL -1), and the 
Figure 9: Corema album (Portuguese Crowberry; 
Camarinha), fruits and leaves 
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growth was kinetically monitorized for 24 hours (section Growth curves in material and 
methods).  
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Figure 10: Growth Curves and growth parameters of S. cerevisiae strains (Control and aSyn-2) with C. 
album leaf PEFs. S. cerevisiae strains incubated with different concentrations of C. album leaf PEFs (μg GAE.mL-1) 
Control [0] (●); aSyn-2 [0] (▲); aSyn-2 [15] (♦); aSyn-2 [30] (×); aSyn-2 [62.5] (-); aSyn-2 [125] (+); aSyn-2 [500] 
(■); Yeast cells were grown in SC liquid medium with  galactose for 24h at 30ºC. a) Grown was kinetically monitored 
hourly by OD measurements at 600 nm and growth curve represented. b); c); d) Growth parameters were determined 
based on the growth curve. b) Final Biomass (OD 600nm), c) Doubling time, d) Lag time. Results represent the mean 
± SD of three independent biologic replicates. *, ** and *** indicate statistically significance between Control and 
aSyn-2, for a p<0.05, p<0.01 and p<0.001 respectively. 
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Considering the data from the growth curve and final biomass, 125 and 500 μg 
GAE.mL -1 are the most harmful to yeast, affecting the growth of the both strains (Fig. 
10a, b).  
Lag time and DT are also affected for 125 and 500 μg GAE.mL -1of C. album leaf 
PEF (Fig.  10c, d), since 500 μg GAE.mL -1 is very toxic, it was not possible to calculate 
the value of lag and DT for this concentration (Fig. 10b).  
Interestingly, some concentrations of PEF increase the final biomass, of aSyn-2 
cells comparatively with cells that were not incubated with PEFs, namely, 15, 30, 62.5 
μg GAE.mL -1 (Fig. 10b). At the same time, it was observed that lag time is reduced by 
15 and 30 μg GAE.mL -1 (Fig. 10d). In contrast, the DT of cells incubate in presence of 
PEFs did not change significantly relative to untreated cells, (Fig. 10c). Furthermore, 
considering the results of the lag time and DT was determined that expression of aSyn 
seem to affect more the replication mechanisms of yeast cells, than the time for adaptation 
to the new conditions. 
To summarize, with this methodology it was possible to determine some 
concentrations of C.album leaf PEF that reduce the toxicity of aSyn and improve cell 
viability.  Thus, our results show C. album leaf polyphenols as potential neuroprotective 
agents, with beneficial effects against aSyn toxicity. Emphasizing, the neuroprotective 
potential of C. album leaf PEFs, previous studies of DSB lab (unpublished data) with a 
different yeast model (p426 GAL-aSyn WT::GFP) reveal a protective effect against aSyn 
toxicity.  Again C. album leaf polyphenols enhance the viability of yeast cells expressing 
WT aSyn. These results are very interesting, because in both models with different 
features C. album leaf PEFs are able to counteract the aSyn induced toxicity. 
 
 Phenotypic Growth assays with polyphenols 
 
Phenotypes are used to determine the sensitivity of cells to a given condition. 
Plating or spotting assays on solid media can be used to track the growth of cells treated 
with toxic agents for example, or to screen non-toxic concentrations of chemicals that 
affect the viability. Spot assays involve the visual inspection of colony size, number and 
the thickness of cells, which allows a visual evaluation of colonies growth under a given 
condition and showing just the cells that are still capable of replication. Consequently, 
spot assays are used as methodology to access cellular viability84,85.  
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In order to evaluate how aSyn expression affected the normal growth of the strains   
and to gain further insight into the protective effect and toxicity of C.album leaf PEF, 
growth phenotypic assays, on solid medium, were performed. Control and aSyn-2 strains 
were incubated with several concentrations of C.album leaf PEF (0, 15, 30, 62.5, 125, 
500 μg GAE.mL -1). Strains were grown as described in the section (Media and growth 
conditions) in material and methods, and subsequently grown for 6 hours in SC medium 
with galactose or raffinose supplemented with C.album leaf PEF. At the end of this 
incubation cells were spotted on galactose and glucose solid medium, and incubated for 
48 hours at 30ºC (section Phenotypic Growth Assays in material and methods) (Fig. 11a).  
The results demonstrate that some concentrations of   C. album leaf PEF are able 
to counteract aSyn toxicity, in two different approaches. (Fig. 11b, c). First, in aSyn-2 
cells grown in SC medium with raffinose, where there is no expression of aSyn, incubated 
with various concentrations of PEF and then placed on solid media containing galactose, 
allowing the expression of aSyn protein. We detect a protective effect of several C. album 
leaf PEF (Fig. 11b), namely 15; 30; 62.5 μg GAE.mL -1. In contrast cells that were not 
treated with PEFs presented a reduced grown (Fig. 11b), emphasizing the toxic effect of 
aSyn, leading to inhibition of yeast growth in aSyn-2 strain. In medium with glucose both 
control and aSyn-2 strain show similar growth rates (Fig. 11b). These results indicate that 
preconditioning with PEFs can increase the viability of yeasts expressing aSyn. Similar 
assays (Fig. 11c) were performed, where cells were incubated with PEFs for 6 hours in 
SC medium with galactose. Therefore, expression of aSyn was induced in the presence 
of PEFs. Still, 15, 30, 62.5 μg GAE.mL -1 of C. album leaf PEFs were able to rescue cells 
from aSyn toxicity. Nevertheless, 30 μg GAE.mL -1of C. album leaf PEF showed the best 
protection, enhancing the growth of aSyn-2 yeasts (Fig. 11b, c). Control and aSyn-2 yeast 
cells that are spotted in glucose solid medium display a normal phenotype, as expected 
(Fig. 11c). PEFs were toxic at concentrations of 125 and 500 μg GAE.mL -1 (Fig. 11b, c), 
like it was already detected in the growth curves. 
In conclusion, it was observe a protective effect of C. album leaf PEF against aSyn 
toxicity and induced death. Some concentration of PEF reveal improvements in growth 
of yeast cells expressing aSyn protein. Consistent with this result, yeast cells expressing 
aSyn who did not receive treatment with polyphenols failed to grow or form colonies.  
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Overall, these results suggest that C. album leaves PEF is an efficient 
cytoprotective agent in the yeast model of PD. This PEF counteracted the cytotoxicity 
induced by aSyn expression. Also in a different yeast model, from DSB lab, expressing 
WT aSyn, C. album leaf PEFs improve the growth phenotype of WT aSyn comparing to 
yeast cells not treated with PEFs (unpublished data). Additionally, based on the results 
from the growth curves and the spot assays, 30 μg GAE.mL -1 of C. album leaf PEF as 
defined as the suitable concentration for further proteomics approaches. 
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Figure 11: Phenotypic growth assay of control and aSyn-2 strains grown in the presence of polyphenol 
fractions. a) Schematic representation of cells growth for 6 hours at 30 ºC, with constant shaking in liquid 
medium containing galactose or raffinose, with several concentrations of PEFs. Cells were serial diluted, 
subsequently 5 μL of each dilution was spotted in solid medium with glucose or galactose and incubated for 
48 hours at 30 ºC. b) Spot assays for control and aSyn-2 strains that grew 6 hours in SC liquid medium 
containing raffinose, supplemented with several concentrations of C. album leaf PEFs. Spotted in solid 
medium with galactose or glucose and incubated for 48 hours at 30 ºC. c) Spot assays for control and aSyn-2 
strains that grew 6 hours in SC liquid medium containing galactose, supplemented with several concentrations 
of C. album leaf PEFs. Spotted in solid medium with galactose or glucose and incubated for 48 hours at 30 ºC. 
Image acquisition was made with Chemidoc XRS and Quantity-one software and the most representative of 
biological replicates is show. 
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 Proteomic Approach 
 2DE protocol optimization  
 
 Before proceeding with proteomic analyses an optimization step was required. 
The aim of these optimization procedures was to preserve as much quality and quantity 
of protein samples during the extraction process, as well as to remove interfering in 
samples. During the protein clarification and extraction process, proteins can easily 
become unfolded, denatured, or damaged. Thus, an appropriate buffer solution need to be 
added to a protein mixture through the extraction process, in order protect the integrity of 
the proteins while separating them from other cell components. Therefore one of the 
improvements that were evaluated consisted in the use of various extraction buffers, in 
particular, Tris-HCL 25 mM, pH 7.4 and ressuspension buffer (RS)[7 M Urea, 2 M 
Thiourea, 4 % (w/v) CHAPS, 2 % (v/v) IPG buffer, 1 mg. mL-1  DNase, 60 mM DTT, 1 
% (v/v) cocktail inhibitor proteases III]. Beyond this optimization, another variant was 
studied, more precisely the use of cleaning protein kit, the 2D Clean-Up kit. Protein 
samples frequently contain interfering agents, like ionic detergents, metal ions, salts, 
lipids, charged polysaccharides, peptides, enzyme substrates, and other agents with 
charge. These agents often lead to poor performance on 2 DE gels, resulting in smeared 
or low resolution gels. Thus, it can be important the use of such kits to remove interfering 
agents and concentrate our samples. For these optimization processes it was used a 
different yeast strain, the wild type S. cerevisiae BY4741. The protein extraction was 
performed as described in the section (Protein extraction) material and methods, using 
different buffers with and within cleaning step. At the end of the extraction  it were 
obtained four samples, (Tris; Tris Clean; RS; RS Clean), two corresponding to each of 
the sample buffers (Tris and RS), one to be quantified, and the other was exposed to a 
cleaning process with 2D clean-up kit (section Sample preparation for Two-dimensional 
Electrophoresis in Material and methods).  
Then, 75 ug of protein of each sample were subjected to a two dimensional gel 
electrophoresis (2-DGE) (section Two-Dimensional Gel Electrophoresis). For protein 
detection, the gels were stained in Commassie Brilliant Blue G for 48 hours with orbital 
agitation (section Commassie Brilliant Blue G in Material and methods). 
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The first information found from these assays is related to the amount of protein 
obtained at the end of extraction. Extraction performed with Tris-HCl yielded about 2 
μg/μL-1 protein. Still, the combination of Tris-HCl extraction followed by a cleaning step 
with 2D clean-up kit, leads to an increase of the concentration of protein (4 μg/μL-1).   
In extraction procedure with RS buffer, the amount of protein obtained was 
approximately 4 μg/μL-1 with the cleaning step this value remained unchanged. Thus, 
with both buffers, Tris-HCl or RS, it was obtained similar amounts of protein. However, 
the cleaning step appears to be important in the extraction with Tris-HCl, once the 
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Figure 12: Representative 2-DGE gels of BY4741 strain cell proteome (75 μg). The gels were CBB stained.  
a) Extraction performed with Tris-HCl buffer. b) Extraction was done with RS buffer. c) The extraction was performed 
with Tris-HCl buffer, and the protein sample was submitted to cleaning step using 2D Clean-Up kit. d) Extraction was 
performed with RS buffer, with subsequently cleaning step using 2D Clean-Up kit. IEF was performed with 3-10 NL IPG 
strips. 
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cleaning step increased the final protein concentration. Contrary to extraction with RS, 
where cleaning the sample did not increase the amount of protein. 
 In addition, through these optimization steps it was possible to observe that the 
quality of our gels varies with the type of buffer is used, and if the sample underwent 
cleaning process or not (Fig. 12). For instance a clear difference between the gels from 
protein extracts that were cleaned (Fig. 12c and 12d), compared to the gels with the same 
sample without cleaning step was observed (Fig. 12a and 12b). In Tris Clean gel (Fig.12c) 
it is possible to observe a greater amount of spots, these are better separated and with a 
much higher resolution compared with Tris condition (Fig. 12a) Similarly, the same 
happened in RS gels (Fig.12b, 12d), where it can be observed that cleaning also allowed 
to obtain a greater number of spots mainly in the alkaline part of the gel with a better 
separation (Fig. 12d). The overall quality of protein separation and spot resolution using 
2D Clean-Up Kit has been shown to be superior to the samples that did not undergo the 
cleaning process (Fig. 12a and 12b). Preparation of protein samples with the kit reduces 
horizontal streaking, improves spot resolution, and increases the number of spots 
detected. However, between the two procedures (Fig. 12c, 12d) it is possible to conclude 
that protein gels performed with samples extracted with Tris-HCl and clarified with 2D 
Clean-Up Kit present a higher spot resolution and definition when compared to the RS 
Clean. Although both samples have been cleaned, the quality of the gels is not similar. 
This difference could be related to the composition of buffers.  
The RS buffer is more efficient probably due to its chaotropic agents, such as urea 
and thiourea allowing a high degree of solubilization of many cellular components, but it 
may be able to extract some components which are of no interest, thus increasing the 
burden of interfering present in the sample, hampering the efficiency of the 2D clean-up 
kit. Taking this into account, the extraction with Tris-HCl buffer combined with the use 
of 2D clean-up kit seems to provide gels with more quality and accurate results. Thus this 
procedure has been implemented in all proteomic approaches in this work. 
 
 Proteome Analysis  
 Protein pattern of Control and aSyn-2 yeast strains with C. album leaf PEFs 
 
Since aSyn is the principal component of LBs, and considering the protective 
effect of C. album leaves PEF against aSyn toxicity, in this work it was investigated the 
cellular responses to expression of aSyn protein and the mechanisms underlying the 
Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: Phosphoproteome alterations    
45 
 
beneficial effects of C. album leaves PEF. To address these questions, we used a 
quantitative proteomics approach based on 2-DGE to screen differentially expressed 
proteins. In order to quantitatively investigate proteome changes of yeast cells in response 
to aSyn expression and the effect of the incubation with C. album leaves PEF, it was 
analysed and compared the proteomes of control and aSyn-2 strains. Both strains were 
grown as mentioned in section (Media and growth conditions) material and methods, 
supplemented with 30 μg of C. album leaf PEF, the ideal concentration based on the 
results of the growth assays. After protein extraction and cleaning process (section 
Sample preparation for two-dimensional electrophoresis in material and methods) four 
different protein samples were collected: control; aSyn-2; that were grown without PEFs 
and control+PEF; aSyn-2+PEF that grown in the presence of PEFs. Therefore, 75 μg of 
each protein sample were submitted to 2-DGE (section Two-Dimensional Gel 
electrophoresis in material and methods). The resulting 2-D gels were stained for total 
protein detection (section Commassie Brilliant Blue G) and compared to identify 
differentially expressed proteins. The results are shown in figure 13. 
 
Figure 13: Representative 2-DGE gel of control strain cell proteome. (75 μg) The gel was CBB stained.  
The normalized volumes were compared to the controls (control strain) in order to estimate variations on 
protein content. In total 22 spots showing statistical significant differences among the four conditions in 
the study (control; control+PEF; aSyn-2; aSyn-2+PEF). Spots that were differentially abundant with 
statistical significance in all replicates were identified by Progenesis SameSpots image analysis. Further 
numbered spots with differential expression pattern (table 3) will be sent for protein identification by MS. 
IEF was performed with 3-10 NL IPG strips.Three independent biologic replicates were done for each 
condition. 
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Through statistical analyses of the proteomes for all treatments it was possible to 
identify a total of 22 spots with different expression levels. The normalized volume for 
each protein spot differentially expressed among conditions and some characteristics of 
proteins such as, pI and MW, are described in table 3. 
Table 3: Normalized volumes for protein spots differentially expressed among the four 
conditions in the study: control; control+PEF; aSyn-2; aSyn-2+PEF, and the respective pI and MW 
(kDa). Differences between treatments are denoted as * p<0.05, **p<0.01 and ***p<0.001. 
Spots number and normalized volumes MW (kDa) i pI ii 
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i) Predicted MW (kDa) was obtained by using an ExPASy tool (http://expasy.org). 
ii) Predicted pI was obtained by using an ExPASy tool (http://expasy.org). 
 
Given the data in Table 3, the 22 identified spots show significant variations in protein 
content between various conditions. It was observed that in each spot can exist more than 
one condition to vary either upregulated or downregulated. Thus we grouped 
quantitatively the total number of spots presenting variation in a given condition under 
study (table 4). 
 
0.0E+00
1.0E+07
2.0E+07
3.0E+07
4.0E+07
5.0E+07
6.0E+07
7.0E+07
Control Control+PEF aSyn-2 aSyn-2+PEF
N
o
rm
al
iz
ed
 V
o
lu
m
e 
20
**
0.0E+00
5.0E+06
1.0E+07
1.5E+07
2.0E+07
2.5E+07
3.0E+07
3.5E+07
4.0E+07
Control Control+PEF aSyn-2 aSyn-2+PEF
N
o
rm
al
iz
ed
 V
o
lu
m
e 
21
**
**
0.0E+00
5.0E+06
1.0E+07
1.5E+07
2.0E+07
2.5E+07
Control Control+PEF aSyn-2 aSyn-2+PEF
N
o
rm
la
iz
ed
 V
o
lu
m
e
22
**
Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: Phosphoproteome alterations    
52 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, minor variations in protein expression appears between control and 
control+PEF. For instance the spot number 5 presented a downregulation on protein 
expression when treated with PEFs, whose expression increases in the presence of aSyn. 
However PEFs not change the protein expression in the presence of aSyn (table 3). On 
the other hand the spot number 8 present a reduction on protein expression when treated 
with PEFs, and this decrease keeps even in the presence of aSyn protein, indicating that 
C. album leaf PEFs are counter the effects of expression of aSyn protein (table 3). 
Looking at the conditions control vs. aSyn-2 it was found that remarkably 90% of 
spots are downregulated by aSyn expression when compared to the control strain, 
indicating a modulatory effect on the proteome expression by aSyn protein. One example 
of that is the spot 18 were it was observed that aSyn expression affect the normal 
expression of the protein, and the treatment with C. album leaf PEFs recovery the normal 
expression of protein spot 18 (table 3). Another example is the spot 19, where it was seen 
the same behavioural, aSyn reduced the protein expression of the spot, and PEFs recovery 
the normal expression. Only the spot number 9 present higher expression in the presence 
of aSyn (table 3). Between the conditions control+PEF vs. aSyn-2+PEF, it was observed 
that spot number 1, 3 and 5 presented higher  protein expression in aSyn-2+PEF condition 
comparatively to control+PEF. In contrast spots number 13 and 14 displayed lower 
expression level relatively to control+PEF (table 3). 
Remarkably, the majority of protein spots (15/22) show significant variations at 
the level of expression between the conditions aSyn-2 and aSyn-2+PEF (table 4). This 
result suggests that most of the proteins change their expression level due to the presence 
of aSyn protein or in response to the presence of the C. album leaves PEF. 75% of these 
fifteen spots presents higher protein expression level in the condition aSyn+PEF 
relatively to aSyn condition (table 4). For instance in the spots 2, 3, 6, 11, 17, 18, 19 and 
21 it was observed a much higher protein expression when cells expressing aSyn are pre-
Conditions 
Nr. of spots with 
significance 
variation between 
conditions 
Upregulated Downregulated 
control vs. control+PEF 2 (0%) 2 (100%) 
control vs. aSyn-2 8 1 (10%) 7 (90%) 
control+PEF vs. aSyn-2+PEF 5 3 (60%) 2 (40%) 
aSyn-2 vs. aSyn-2+PEF 15 10 (75%) 5 (25%) 
Table 4: Number of spots with expression variations in the respective conditions under study: 
control; control+PEF; aSyn-2; aSyn-2+PEF. 
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treated with PEFs. This may indicate that the PEFs are allowing the recovery of protein 
expression affected by aSyn expression. On the other hand 25% of spots treated with 
PEFs are downregulated in relationship to aSyn condition. Examples of that are the spots 
8, 13, 14, 16 and 22 where it was observed that the treatment with PEFs reduce the protein 
expression when compared to aSyn condition (table 3). 
Altogether, treatment with the C. album leaves PEF appears to restore the normal 
level of expression in all the 15 spots, either by increasing or decreasing the expression 
level. This result is very interesting because both aSyn protein and C. album leaves PEF 
appears to modulate the expression of the same protein, but in opposite ways, which 
indicates that possibly the PEFs may be acting in signalling pathways similar to aSyn. In 
fact, polyphenols can activate signalling pathways underlying neuronal survival, for 
example they are capable of inducing neurogenesis trough the activation of PI3 kinase-
Akt59,63. Proteasome impairment is one of the characteristics of the abnormal deposition 
of misfolded proteins, like aSyn and some studies show an increase in the clearance of 
these misfolded proteins due to an increase in proteasome activity, promoted by 
polyphenols53. This may also be a possible mechanism of action of C. album leaves PEF.  
Despite these promising results we have to wait for the results of mass 
spectrometry, in order to realize what proteins and subsequent signaling pathways are 
being affected for aSyn expression and C. album leaves PEFs. The proteins whose relative 
abundance was consider to vary in response to aSyn expression or C. album leaves PEF 
treatment will be sent for protein identification by MS. 
 
 SDS-PAGE-detection of phosphoproteins 
 
In order to study the presence phosphorylation activity in control and aSyn-2 
strains, and find possible clues about the effect of polyphenols in our model yeast strains, 
we performed a SPS-PAGE and subsequently stain the gel with Pro-Q DPS (section Pro-
Q® Diamond in material and methods). Yeast cells were grown as described in section 
Media and growth conditions. After protein extraction and quantification, 10 μg of protein 
samples of all the conditions (control; control+PEF; aSyn-2; aSyn-2+PEF) were 
subjected to an SDS-PAGE (section SDS-PAGE in material and methods). The results 
are show in figure 14. 
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Considering the results, it was observed that polypeptides which exhibit 
phosphorylation activity among the four conditions are found in the 23 kDa region. Slight 
differences for this polypeptides in terms of phosphorylation intensity were detected 
between yeast cells treated with C. album leaves PEF, respectively, control+Ca and aSyn-
2+Ca and yeast cells without treatment (Fig 14). This result may indicate that C. album 
leaves polyphenols can modulate the phosphorylation activity in control and aSyn-2 yeast 
cells. Forward, we will try to relate and understand this result by studying the 
phosphoproteome of yeast strains. 
 
 Phosphoproteome of control and aSyn-2 yeast strains with C. album Leaf 
PEFs 
 
Knowing that the most abundant modification of aSyn in LBs is the 
phosphorylation of serine 129, it becomes pertinent to study the phosphorylation network 
of the proteome of our Parkinson yeast model, to seek for modulations of phosphorylation 
mediated by C. album leaves PEF. Thus, 2-D gels of control; control+PEF; aSyn-2 and 
aSyn-2+PEF were stained with Pro-Q DPS (section Pro-Q® Diamond in material and 
45
23
66
14
Control+PEF aSyn-2+PEFControlMW aSyn-2
Figure 14: Protein phosphorylation profile of yeast strains incubated with C. album leaves 
PEF (control+PEF; aSyn-2+PEF) and without treatment (control; aSyn-2). 10 μg of protein 
sample of each condition was applied. SDS-PAGE gel was stained with Pro-Q DPS. Images of the 
gels were scanned in a laser imager with 532-nm excitation and 580 bandpass emission filter FLA-
5100 Fuji Photo Film Co, Ltd. A representative image is show with two independent biologic 
replicates for each condition. 
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methods).  The utilization of Pro-Q DPS allowed the detection and quantification of 
phosphoproteins in all the conditions tested. The results are shown in figure 15.  
Preliminary results of the phospoproteomes analysis of all treatments allowed to 
detect a total of 10 protein spots with variance in phosphorylation signal. The normalized 
volume for each protein spot differentially expressed among conditions and some of the 
characteristics of proteins such as pI and MW are described in table 5. 
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Figure 15: Representative 2-DGE gel of empty strain phosphoproteome (75 μg). The gel was stained 
with Pro Q-DPS.  The normalize volumes were compared to the controls in order to estimate variations in 
phosphorylation levels. In total 10 spots exhibited phosphorylation signal between the four conditions in 
the study (control; control+PEF; aSyn-2; aSyn-2+PEF). IEF was performed with 3-10 NL IPG strips. 
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Table 5: Normalized volumes for protein spots presenting phosphorylation levels among the 
four conditions in study: contro; control+PEF; aSyn-2; aSyn-2+PEF, and the respective pI and MW 
(Kda). 
Spots number and normalized volumes 
MW 
(kDa) 
i 
pI 
ii 
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i) Predicted MW (kDa) was obtained by using an ExPASy tool (http://expasy.org). 
ii) Predicted pI was obtained by using an ExPASy tool (http://expasy.org). 
 
Considering the data of the table 5, and analysing the levels of phosphorylation 
exhibited by each protein spot in the respective condition, a trend was observed over the 
10 spots. In fact, the majority of protein spots (8/10) of the condition aSyn+PEF displayed 
a lower phosphorylation intensity with respect to the proteins spots of aSyn condition. 
The modulation in the intensity of phosphorylation activity of the proteins presented by 
yeast cells that were incubated with C. album leaves PEF, may reflect some type of 
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modulation in phosphorylation pathways by C. album leaves PEF. Also, the aSyn 
expression increases the levels of phosphorylation in almost all protein spots (9/10) in 
comparison to control strain and control+PEF. Since there are several kinases involved in 
aSyn phosphorylation, especially casein kinases 2 (CK2) and 1 (CK1), and some studies 
related an inhibition of the activity of this kinases, mediated by polyphenols86,87, possibly 
C. album leaf PEFs are interfering with this pathways. Maybe PEFs are acting as 
“competitive inhibitors” of phospho-donor substrate ATP, preventing the binding of 
kinase to receptor, and stopping the respective signalling cascade28,86,87. This may be a 
mechanism that lead to decreased phosphorylation in cells treated C. album leaves PEF. 
 
 C. album leaves PEF effects on aSyn protein  
 
In order to assess how treatment with polyphenols affect the behaviour/expression of 
aSyn protein, a western blot was performed. Control and aSyn-2 yeast cells were growth 
as cited in section (Media and growth conditions) material and methods, supplement with 
30 μg of C. album leaf PEF. Then 10 μg of total protein was submitted to SDS-PAGE. 
After the electrotransfer of polypeptides, immunodetection was performed as describe in 
section (Western Blot and Immunodetection) material and methods. The results are show 
in figure 16.  
 
 
 
 
When yeast cells expressing aSyn protein were treated with C. album leaf PEF it was 
observed a reduction in the content of aSyn protein. The relative densitometric intensities 
(Fig.16b) demonstrated that 30 μg C. album PEFs effectively reduced the level of aSyn 
protein in aSyn-2 yeast cells. Moreover and based on the previous results of 
b) a) 
PGK
aSyn
45 kda
17 kda
PGK:     aSyn = 10678.075
aSyn+PEF = 17799.309
aSyn:     aSyn = 14009.530
aSyn+PEF = 10967.258 
aSyn
PGK
= 1,31
aSyn+PEF
PGK
= 0,61
Figure 16: aSyn expression profile treated with C. album leaf PEF. aSyn expression levels in yeast cells 
assessed by western blot analysis of total protein extract. a)  aSyn expression levels of control and aSyn-2 yeast 
cells subjected to the treatment with C. album leaf PEFs. b) Relative densitometric intensities. PGK was used 
as an internal loading control. Protein siganls were detected using the chemiluminescence detection kit 
FemtoMax Super Sensitive Chemiluminescent HRP Substracte. A representative image is shown. 3 independent 
biological replicates were performed.
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phosphoprotein analysis, is clearly very interesting to evaluate aSyn phosphorylation 
attenuation due to PEFs. This can be done by western blot targeting several known 
phosphorylation sites on aSyn protein, using specific antibodies. For instance S129, Y39, 
Y125, and Y133. Considering results of altered expression of aSyn and previous results 
from DSB lab, where PEFs incubation reduce the percentage of cells with aSyn 
inclusions, both in yeast model and H4 neuroglioma cells. Moreover, C. album leaf PEF 
increased the degradation of aSyn by autophagy in yeast and H4 cells46.  These 
observations, suggest that protection promoted by C. album leaf PEF may be related with 
increased degradation of aSyn by autophagy.  
aSyn can be degraded either by the UPS or by autophagy pathway. Interestingly, 
overexpression of aSyn causes impairment in proteasome system, thus autophagy 
pathway is required to compensate the increased protein accumulation and potential 
damage. Autophagy is a key degradation route for a wide range of intracytoplasmic 
aggregate proteins, and is considered as a pro-survival mechanism to protect cells from 
cellular stress or poor nutrient conditions88.  Indeed recent evidence suggest that 
autophagy is mostly a cytoprotective mechanism that allow cells to recycle damaged 
organelles89,90. 
Several polyphenols have been associated with an increase in autophagy pathway, for 
instance resveratrol and curcumin88–90. This regulation in autophagy pathway by 
polyphenols it is related to the activation of Sirtuins, especially SIRT-1. Sirtuins are a 
class III histone deacetylases and have been show to regulate various physiopathological 
processes, including autophagy pathway. Once activated, SIRT-1 can deacetylate 
essential autophagic modulators such as ATG5 and ATG7, promoting autophagy. 
Furthermore, SIRT-1 deficient mice have accumulation of damages organelles and 
disruption of homeostasis89,91,92 (Fig.17). Another way to increase autophagy in cells is 
related to downregulation of mammalian “Target of Rapamycin” (mTOR), an 
evolutionarily conserved protein kinase for modulating autophagy. Curcumin efficiently 
silence mTOR enchaning autophagy and resveratrol suppressed mTOR signalling in a 
S1RT-1-dependent manner88–91. Taken all these clues into consideration, it is reasonable 
to ponder that C. album leaf PEFs can enhance autophagy in yeast cells expressing aSyn, 
in a similar way to resveratrol for instance, leading to a decrease in aSyn inclusions, 
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ameliorating the cell fitness (Fig.17). Overall modulation of autophagic pathways by 
polyphenols could be a novel neuroprotective strategy for PD.  
 
 
Based on this information’s, in further analysis complementary to 
phosphoproteomics, it’s possible to target this signalling intermediaries. For instance the 
induction of autophagy by C. album leaf PEFs can be determined by detecting protein 
levels of the autophagosomal membrane form of microtubule-associated protein 1 light 
chain 3 (LC3) using immunoblotting assay with anti-LC3 antibody90. Also we can access 
the expression level of ATG5 and ATG7, which are directly modulated by SIRT-
1activity88. Another possibility, is the use of transmission electron microscopy in order to 
detect authophagosome structures of authopagy in cell lines treated with C. album leaf 
PEFs89,90. 
 
 
 
 
mTOR
ATG proteins
Autophagy
PDClearance of aSyn 
C. Album
Leaf PEFs
C. Album
Leaf PEFs
Sirtuins
Curcumin
Resveratrol
Figure 17: Schematic model of the role of Curcumin and Resveratrol in autophagy and possible 
modulation in autophagy mediated by C. album leaf PEFs. Resveratrol causes activation of Sirtuins, more 
precisely SIRT-1, followed by the induction of ATG proteins, essentials for the autophagic machinery. This 
pathway may be affected in the same way due to C .album leaf PEFs (dashes line). Also mTOR is downregulated 
by curcumin, and potentialy could be downregulated by C. album Leaf PEFs (dashes line). Induced autophagy 
enhances the clearance of aSyn, thereby may contribute to the neuroprotection on PD. 
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Final consideration and future perspectives. 
 
Neurodegenerative diseases are among the most complex and puzzling of human 
disorders. Currently there is no effective treatments for these devastating illness, and are 
thus a social and economic burden for modern society, and one that will certainly get 
worse in the future due to the ageing of population. Among neurodegenerative disease, 
PD is one of the most prevalent worldwide. PD is a chronic progressive 
neurodegenerative disorder characterized by aSyn inclusions known as Lewy bodies, 
which are associated with progressive loss of dopamine neurons in SNpc. The selective 
neurodegeneration featuring PD has been linked to various intracellular processes 
particularly, mitochondrial dysfunction and subsequent oxidative stress. As well 
conformational changes of proteins affecting the UPS. All this with the aggregation of 
aSyn protein in the spotlight.  
Since, current PD medications treat symptoms, none halt or retard dopaminergic 
neuron degeneration, there is an urgent demand for the identification of novel therapeutic 
agents that are capable of counteracting the progression of PD.  
Polyphenols are the most abundant pytochemiclas in the human diet, and appear as 
possible candidates for protective agents in PD. The consumption of polyphenol-rich 
foods, especially fruits and vegetables, translates into benefits for human health. 
Polyphenols besides to be free radical scavengers, are now considered to modulate 
cellular mechanism of action, such as modulation of signalling pathway related to cell 
survival. C. album a Portuguese native species were chose for this study in order to 
evaluate the protective effects against aSyn protein, mediated by PEFs from C. album 
leaves. S. cerevisiae was used as a eukaryotic cell model to study the effects of aSyn 
expression and the bioactivity of PEFs. 
Thus in this work we focus on the changes caused by aSyn protein on the proteome 
and phosphoproteome of yeast cells expressing two copies of aSyn protein, and also on 
the alterations in the same proteomes mediated by treatment of yeast cells with C. album 
leaf PEFs. With this analysis it is possible to study the protein network of our PD yeast 
model, and modulations mediated by PEFs, that will allow understanding the influence 
of these protective compounds in molecular mechanisms with this disease in particularly. 
Yeast growth parameters analysis revealed that aSyn expression is toxic and drastically 
decrease the growth of yeast cells comparatively to the control strain. Remarkably, it was 
demonstrated in this work that treatment with C. album leaf PEFs reduce aSyn induced 
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toxicity and enhances the viability of yeast cells. Our data from the growth curves and 
phenotypic assays validate that C. album leaf PEF is a promising protective agent against 
aSyn induced toxicity.  
Through the proteomic tools used in this work was possible to study the proteome 
and phosphoproteome of our yeast cells in order to find changes in protein expression 
mediated by aSyn protein expression and C. album leaf PEFs.  The analysis of the total 
proteome by 2DGE revealed 22 proteins spots that presented variations in their expression 
pattern among the conditions studied. Interestingly, it was found that 90% of spots are 
downregulated by aSyn expression when compared to the control strain, indicating that 
the expression of aSyn protein is affecting normal expression of these proteins. Even more 
fascinating is the fact that treatment of aSyn-2 yeast cells with C. album leaf PEFs reverse 
the effects of aSyn on protein expression, allowing to restore protein expression to similar 
levels presented by the control strain.  
Thereby becomes evident that C. album polyphenols exert their neuroprotective 
actions, likely by the modulation of intracellular signalling cascades which control 
neuronal survival, death and differentiation57,93,94.  
In terms of phosphoproteome, with the preliminary results analysis it was possibly 
to detect 10 proteins that showed significant changes phosphorylation level. Remarkably 
the phosphoproteomes from yeast cells incubated with polyphenols from C. album leaf 
PEFs (aSyn-2+PEF) displayed reduced phosphorylation levels comparatively to yeast 
cells not treated (aSyn-2). Interestingly proteins of aSyn-2 strain which were not treated 
with polyphenols exhibit a higher level of phosphorylation. This preliminary findings 
suggest that C. album leaf PEFs are able to reduce the phosphorylation activity in our PD 
yeast model and counteract the increased phosphorylation levels mediated by aSyn 
expression.  
This effect mediated by PEFs may be related to their ability of modulating 
signalling pathways linked to phosphorylation. Further studies using C. album leaf PEFs 
and targeting single phosphorylation sites in aSyn protein can provide information 
regarding the interactions of PEFs with specific sites of phosphorylation.  
Moreover, upon incubation with C. album leaf PEFs there is a reduction in the 
level of aSyn protein present in yeast cells expressing the protein. Given this result and 
previous observations from DSB lab indicating that PEFs reduces the percentage of yeast 
cells with aSyn inclusions, suggest that the protection promoted by C. album leaf PEFs 
may be related with increased degradation of aSyn protein by autophagy46. 
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Although the results obtained from proteomic approaches, various enhancements 
can be made to obtain more accurate and reliable results. For instance, could be interesting 
to fractionate our sample, in order to reduce the complexity of protein/peptide mixtures 
and separate various groups of proteins for subsequent analysis. Also, detect 
phosphorylation species directly from complex sample mixtures it’s really difficult since 
phosphorylation often occurs at low stoichiometry.  Thus enrichment of phosphoprotein 
and phosphopeptides techniques can be implemented71,74,76. Furthermore, the 
development of Phos-tag™ techniques offers a new method to detect phosphorylation 
activity95. This method provides a phosphate affinity SDS-PAGE for mobility shit 
detection of phosphorylated proteins. All these methodologies/optimizations can be used 
in further studies in order to complete and improve the results obtained in this work. 
Intense efforts are being made to unravel the mysteries underlying 
neurodegenerative diseases. However, there still much to be learnt and discovered. 
Further technological advances are still required to lead to final goal of reaching 100% 
protein coverage in proteome studies, allowing characterization of all protein species in 
a given organism. This is of extreme importance to better understand the biologic 
mechanisms involved in PD and other neurodegenerative diseases, and more importantly, 
to discover novel agents for therapeutic interventions. 
Budding yeast has been successfully used to perform studies in this work, it was 
demonstrated that polyphenols from C. album leaves can improve the viability of yeast 
cells expressing aSyn protein, and thus, protect yeast cells from aSyn induced toxicity. 
Thereby elucidating the beneficial health properties and neuroprotective potential of plant 
polyphenols. 
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            Annex 1 - Western Blot - aSyn Immunodetection 
 
 With the purpose of verifying the expression of aSyn protein by strain aSyn-2 
with different galactose concentrations in the culture SC medium, immunodetection in 
membrane was performed (section Western blot and immunodetection). Control and 
aSyn-2 yeast cells were growth as mentioned in section Media and growth conditions, 
and shifted to SC liquid medium supplemented with various galactose concentrations (0 
%; 0,5 %; 1 % and 2 %). After growth, protein extraction and subsequent quantification 
was done using Lowry’s method (section Protein quantification in material and methods). 
Samples with 10 μg of total protein was submitted to SDS-PAGE, and after the 
electrotransfer, immunodetection was performed using antibodies anti alpha-synuclein to 
detect expression of aSyn protein (section Immunodetection) (Fig.18). 
 
 
 
 
 
 
It was found that aSyn expression in aSyn-2 strain yeast cells only occurs on 
media containing galactose, as expected. It was also observed that the expression of the 
protein increases with the increase of galactose concentration present in the medium 
(Fig. 18).  As predictable, control strain don’t show any expression of aSyn protein. 
These results confirms that galactose at a concentration of 2% is the optimal condition 
to induce aSyn expression. 
 
 
45 kDa
17 kDaaSyn
PGK
aSyn-2 strainControl strain
Figure 18: aSyn expression profile. aSyn expression levels in yeast cells assessed by 
western blot analysis of total protein extract. Different concentrations of galactose were used to 
optimize the better condition to express high levels of aSyn. PGK was used as an internal loading 
control. Protein siganls were detected using the chemiluminescence detection kit FemtoMax Super 
Sensitive Chemiluminescent HRP Substracte. A representative image is shown. 
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